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 i 
Abstract 
 
Background: Signal transducer and activator of transcription (STAT)3 activation 
triggers transcription of interleukin (IL)-17 which is crucial for mounting protective 
immune responses against fungi. Several mutations affecting the STAT3/IL-17 pathway 
have been reported, resulting in selective susceptibility to fungal (Candida) infection 
characteristic of Chronic Mucocutaneous Candidiasis (CMC). Patients with autosomal 
dominant (AD)-CMC have defective T helper (Th)-17 responses (Ng et al, JACI 2010) 
and harbour gain-of-function (GOF) STAT1 (rather than STAT3) mutations (van de 
Veerdonk et al NEJM 2011), leading to hyper-phosphorylation of STAT1 (Smeekens et al 
PLosOne 2011). How this affects STAT3 or leads to decreased IL-17 production is 
unknown. 
 
Objective: To assess how GOF-STAT1 mutations affect STAT3 activation, 
DNA-binding, gene expression, cytokine production and whether this can be 
epigenetically modified. 
 
Approaches: Peripheral blood mononuclear cells (PBMCs) or Epstein-Barr virus 
(EBV)-transformed cell lines were stimulated with various cytokines (IL-23, IL-6, 
IL-21, IL-27, IFN-α, IFN-γ) in the absence or presence of fludarabine (a STAT1 
inhibitor) or trichostatin A (a histone deacetylase inhibitor, HDACi). Activation of 
STAT1 and STAT3 was measured by western blotting (WB). DNA-binding of STAT1 
and/or STAT3 was evaluated using electrophoretic mobility shift assay (EMSA), 
TransAm STAT3 kit and chromatin immunoprecipitation (ChIP) assay. STAT3-inducible 
gene (RORc, IL-17, IL-22, IL-10, c-Fos, SOCS3, c-Myc) and STAT1-inducible gene 
(CXCL10, IRF1) expression was assessed using quantitative real time-polymerase chain 
reaction (qRT-PCR). Gene silencing was performed with small interfering RNA (siRNA) 
targeting HDAC1, 2 and 3. Candida albicans-induced cytokine (IL-17, IL-22, IL-10) 
production was measured by enzyme-linked immunosorbent assay (ELISA). 
 
 ii 
Key Findings: GOF-STAT1 mutations lead to hyper-phosphorylation of STAT1 and 
delayed dephosphorylation. Mutations decrease STAT3-induced gene expression and 
Th-17-mediated cytokine production without affecting STAT3 phosphorylation, nuclear 
accumulation or DNA-binding to a STAT-consensus binding site - human sis-inducible 
element (hSIE). The disrupted STAT3 function can be modified either by enhancing 
acetylation or inhibiting STAT1 activation.  
 
Conclusion: GOF-STAT1 mutations impair STAT3 function, which can be rescued by 
enhancing acetylation and/or inhibiting STAT1. These findings are the likely 
mechanisms underlying decreased Th-17 (IL-17A and IL-22) cytokine production and 
susceptibility to fungal infections in CMC. 
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CHAPTER 1 GENERAL INTRODUCTION 
 
1.1 Candida and Chronic Mucocutaneous Candidiasis 
Candida albicans is a commensal ubiquitous fungal organism, found naturally in the 
intestinal tract of all people, often colonizing the skin and the mucosal surfaces of 
normal individuals, without causing disease. However, Candida is an opportunistic 
organism and in permissive circumstances it can cause infections [1].  
 
1.1.1 Infections caused by Candida 
In immunocompromised individuals such as those with primary or secondary immune 
deficiencies, Candida infections can cause a spectrum of clinical presentations, ranging 
from localized mucocutaneous infections to disseminated and/or invasive disease [2].  
 
Primary versus secondary Candidiasis: Primary immunodeficiency diseases (PIDs) 
are genetic, inborn errors of innate and/or adaptive immunity that render their hosts 
susceptible to infections and other immune-mediated diseases including autoimmunity 
and exaggerated inflammatory responses [3]. Conventional PIDs were defined by a 
distinct immunological phenotype resulting in a broad susceptibility to range of 
microorganisms. As a conventional PID, Severe Combined Immune Deficiency (SCID) 
has been reported to predispose to candidiasis although, importantly, these patients are 
also simultaneously susceptible to a wide range of microorganisms [4, 5] i.e. do not 
have a selective susceptibility to Candida. Secondary Candida infections can be 
precipitated by a range of factors including dentures, antibiotics, immunosuppressive 
drugs and human immunodeficiency virus (HIV) infection/acquired immunodeficiency 
syndrome (AIDS) [6, 7], where permissive circumstances promote Candida growth. 
 
Mucocutaneous Candidiasis is seen in patients with oral Candida infection, known as 
thrush, but can also present as persistent mucosal infections affecting vaginal, 
esophageal and gastrointestinal mucosae. More seriously, disseminated Candida 
infection - Systemic Candidiasis is encountered in patients with phagocytic defects 
affecting neutrophils, monocytes and macrophages [3]. It involves the hematogenous 
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spread of Candida albicans to multiple organs, including the brain, kidneys, heart, liver 
and lungs and leads to a high mortality [8].  
 
1.1.2 Primary immunodeficiency syndromes of CMC as a model for studying the 
Candida immunity 
Selective susceptibility to Candida infections is well recognized in PID syndromes of 
Chronic Mucocutaneous Candidiasis (CMC), where patients suffer with chronic, 
persistent or recurrent, debilitating infection of the skin, nails and mucous membranes 
with Candida (usually albicans) [9, 10]. As opposed to conventional PIDs, CMC is 
defined as a “non-conventional” PID [11], manifesting as narrow susceptibility to 
infection with weakly pathogenic microbes. Indeed, non-conventional PIDs are ideal 
models to understand individual susceptibility to common infections, which can 
elucidate the genetic basis of impaired immunity to specific infections with a 
genotype-to-phenotype approach [1]. As a good example of non-conventional PIDs, 
understanding the aetiology and pathogenesis of CMC can unravel the immunological 
pathways mediating human immunity to fungi. Until recently, classifications of CMC 
were mostly based on the time of onset and endocrine organ involvement, the largest 
subgroups being patients with autosomal dominant (AD)-CMC with or without thyroid 
disease, patients with the Autoimmune Polyendocrinopathy Syndrome type I (APS1) 
also known as the Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy 
syndrome (APECED) and sporadic patients with isolated CMC. 
 
1.2 Protective immunity to Candida infections 
Protective immunity to Candida involves both innate and adaptive cellular and humoral 
immune responses. Current data suggest that protection against disseminated diseases is 
mediated primarily by innate immune mechanisms (such as neutrophils) [12]. In 
contrast, protection against mucocutaneous disease relies on cell-mediated immunity 
specially T cells [13]. 
 
1.2.1 Role of the innate immune system 
The innate immune system can recognize a range of conserved fungal 
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pathogen-associated molecular patterns (PAMPs) [14] and initiate a rapid response to 
activate inflammatory cells that have a dual role of eliminating the invader and 
triggering the appropriate adaptive immune responses. Mannans, mannoproteins, 
β-glucans and chitin, considered to be PAMPs, are essential structures of Candida cell 
walls [15]. Chitin and β-glucans provide the necessary rigidity of the internal skeleton, 
whilst a heavily mannosylated layer of mannoproteins covers this layer and forms the 
surface. These different Candida cell wall components can be recognized by host 
pattern recognition receptors (PRRs), including the Toll-like receptors (TLRs), the 
C-type lectin receptors (CLRs) and the NOD-like receptors (NLRs) ( Fig 1.1) [16, 17]. 
 
 
Figure 1.1 Pattern recognition receptors sensing Candida albicans at the innate 
immune system [18]. 
TLR, Toll-like receptor; MyD88, myeloid differentiation factor 88; Syk, spleen tyrosine 
kinase; CARD9, caspase recruitment domain-containing protein 9; MAL, MyD88 
adaptor like; IRAK, IL-1 receptor associated kinase; TRAF, TNF receptor associated 
factor; TAK, TGF-β activated kinase; TRIF, Toll-IL-1 receptor domain containing 
adaptor inducing IFN-β; TRAM, TRIF related adapter molecule; TBK, TRAF family 
member associated NF-κB activator binding kinase; IRF, IFN response factor; MR, 
mannose receptor; DC SIGN, DC specific intracellular adhesion molecule grabbing 
non-integrin. 
 
TLRs were the first PRRs to be identified [19]. Mammalian TLRs contain leucine-rich 
repeats in the extracellular domain of innate immune cells, which can recognize 
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microbial or fungal structures. TLRs share a cytosolic Toll-interleukin (IL)-1 receptor 
domain with IL-1 and IL-18 receptors responsible for activation of downstream 
signaling pathways [20]. Following the recognition of ligands by TLRs, it can activate 
the myeloid differentiation factor 88 (MyD88)-dependent pathways leading mainly to 
the stimulation of pro-inflammatory cytokines. Some TLRs stimulation of an alternative 
route through the Toll-IL-1 receptor domain containing adaptor inducing IFN-β (TRIF) 
- TRIF related adapter molecule (TRAM) pathways which trigger Type I interferons 
(IFNs) signaling [21]. Among the TLR families, TLR2, TLR4, TLR9 and heterodimers 
containing TLR1 and TLR6, have been reported to mediate the recognition of Candida 
PAMPs [22]. TLR2 and TLR4 were thought to have a host defense role against fungi 
via inducing cytokines such as TNF-α and IL-1β [23]. TLR2 from myeloid cells was 
reported to recognize the phospholipomannan component of Candida albicans cell 
walls [24], whilst TLR4 recognizes the mannan structures [25]. In addition, TLR9 can 
recognize fungal DNA from Candida albicans, which subsequently can induce the 
production of inflammatory cytokines by dentritic cells (DCs) [26]. A partial role of 
TLR1 and TLR6 has been demonstrated in recognition of Candida albicans in vitro 
and induction of cytokines by macrophages. However, there was no increased 
susceptibility to infection observed from the absence of these receptors from genetically 
manipulated animals [27]. 
 
CLRs are central for fungal recognition of carbohydrate structures. CLR family 
members include Mannan receptor (MR), Dectin-1, Dectin-2, DC-SIGN, Mincle and 
Galectin-3. Among these receptors, Dectin-1 and Dectin-2 are important in inducing 
cytokines that drive inflammation and adaptive immunity to protect the host from 
Candida infections. This is dependent on the activation of a common signaling pathway 
involving spleen tyrosine kinase (Syk), caspase recruitment domain-containing protein 
9 (CARD9) and nuclear factor (NF)-κB [28]. Dectin-1 binds β-1,3-glucan and activates 
the Syk-CARD9 signaling in innate immune cells, promoting interleukin IL-23 
production and subsequent T helper type (Th)-17 cells induction in human Candida 
immunity [29, 30]. Dectin-2 recognizes high-mannose structures that bind hyphal forms 
of fungi and activate NF-κB via the Fc receptor γ-chain (FcRγ)-Syk-CARD9 pathway, 
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thus activating Th-17-inducing activity against Candida infections in murine models 
[31].  
 
Collaborative responses between PRRs: Notably, certain TLRs cooperate with CLRs 
to mount antifungal immunity. Dectin-1 can collaborate with TLR2 or TLR4 to trigger 
cytokine production upon recognition of Candida albicans [32]. In addition, Galectin-3 
and MR are also involved in supporting TLR2-mediated innate cell responses to 
Candida infections [18, 33]. However, further research is needed to better clarify the 
relationships between PRRs and their functions in Candida immunity.  
 
1.2.2 Role of the adaptive immune system 
Adaptive immunity to Candida infections relies on the induction of cellular immunity, 
appropriate cytokines and effector phagocytic cells. Studies suggest that the Th-1 and 
Th-17 cells and the induction of their associated cytokines are required for host 
resistance to Candida. 
 
Th-1 cells and related cytokines implicated in Candida infections: Th-1 cells are 
induced by IL-12, regulated by the transcription factor T-bet and produce IFN-γ that 
confers immunity to intracellular pathogens. Experimental study in animal models 
highlighted Th-1-mediated immunity as crucial in immunosurveillance and protection 
against Candida albicans [34]. Previous research in humans suggested that patients with 
CMC have impaired production of Th-1-inducing cytokines, which could results in an 
inability to mount protective cell-mediated responses and failure to clear Candida [35]. 
However, the role of Th-1 cells in mucosal antifungal immunity has now largely been 
replaced by Th-17 cells [33].  
 
Th-17 cells and related cytokines implicated in Candida infections: Th-17 cells 
develop in the presence of IL-1β, transforming growth factor (TGF)-β and IL-6 that 
requires several transcription factors including signal transducer and activator of 
transcription (STAT)3 and retinoic acid receptor (RAR)-related orphan receptor γt 
(RORγt) (a similar protein that in humans is encoded by the RORc gene) [36]. Th-17 
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cells are further expanded and maintained in the presence of the IL-12-related cytokine, 
IL-23 [37]. Cytokines produced by Th-17 cells including IL-17A, IL-17F and IL-22 can 
induce chemokine production at sites of Candida infections and initiate the recruitment 
of neutrophils. Therefore, Th-17 cells are believed to play a crucial role in fungal 
immunity [38, 39], although they are also associated with pathogenesis of many 
autoimmune and allergic disorders [36, 40]. Accumulating data regarding immune 
defects in CMC have highlighted IL-17 signaling in host defense against Candida 
albicans [41, 42] (see below). 
 
1.3 Recent advances in understanding immune defects in PIDs with CMC 
Studying patients with inborn errors of immunity has recently led to a major 
breakthrough in our understanding of immune defects underlying CMC (Fig 1.2). 
 
1.3.1 Hyper IgE syndrome – STAT3, DOCK8 and Tyk2 mutations 
Hyper IgE syndrome (HIES), also called Job’s syndrome is a PID characterized by 
recurrent skin abscesses and severe lung infections that result in pneumatoceles, very 
high concentrations of the serum antibody immunoglobulin (Ig) E and CMC. 
Inheritance of HIES can be autosomal dominant (AD) or autosomal recessive (AR) 
[43].  
 
AD-HIES with STAT3 mutations: In this group, CMC is the second most frequent 
presentation, affecting about 80% of AD-HIES patients [44]. Dominant-negative 
mutations in the STAT3 gene were found to be responsible for AD-HIES [45, 46]. It is 
of note that these mutations are heterozygous as homozygous STAT3 mutations are 
lethal and animal models of STAT3 gene knock-out (KO) are tissue specific. Several 
groups have shown STAT3 mutations result in a markedly reduced number and function 
of Th-17 cells and increased susceptibility to Candida albicans (but also Staphylococcus) 
in HIES [47, 48]. Murine models have confirmed the role of Th-17 T cells in immunity 
to both systemic and mucosal Candida albicans infections [49], and mouse 
STAT3-deficient CD4
+
T cells are unable to differentiate into IL-17-producing T cells 
[50]. Therefore, identification of the genetic basis of AD-HIES paved the way for 
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cellular and molecular dissection of its associated CMC phenotype. 
 
AR-DOCK8 mutations: Mutations in the gene encoding the dedicator of cytokinesis 8 
protein (DOCK8) have been demonstrated in AR-HIES [51]. With AD-HIES, it shares 
hyper-IgE, eosinophilia, and recurrent Staphylococcal infections, but is distinguished 
from AD-HIES by increased susceptibility to viral infections (Herpes simplex, 
Molluscum contagiosum) and the lack of connective tissue and skeletal abnormalities. 
Similar to the heterozygous STAT3 mutations in HIES, the homozygous mutations in 
DOCK8 show substantially reduced numbers of Th-17 cells and present clinically with 
CMC infections [52]. It has been reported that this mutation impairs normal 
immunoglobulin class-switching responses, partly through STAT3-dependent signaling 
cascades [53], however, the function of DOCK8 is still unclear.  
 
Tyk2 mutations: One patient who has tyrosine kinase (Tyk)2 deficiency [54] has been 
reported with characteristic of HIES and Mendelian susceptibility to mycobacterial 
disease (MSMD), which is also associated with defects in Th-17 cells and susceptibility 
to CMC [55]. However, a recent study reported a second patient with Tyk2 deficiency 
without HIES characteristics [56]. 
 
1.3.2 CMC – CARD9 and Dectin-1 mutations 
The Dectin-1/Syk complex engages CARD9, promoting pro-inflammatory cytokine 
production and subsequently inducing the differentiation of T cells into IL-17-producing 
T cells [57]. AR-CARD9 deficiency in humans was recently reported in a large 
multiplex Iranian kindred with CMC and invasive candidiasis, possibly due to the lack 
of CARD9 expression on macrophages and DCs [30]. In addition, Dectin-1 deficiency 
was reported in a family, where four women with either recurrent vulvovaginal 
candidiasis or onychomycosis [29]. Although with the allele prevalence in the healthy 
population of 3-8%, Dectin-1 deficiency has been characterized as a polymorphism and 
a risk factor rather than a PID. Cytokines induced IL-17 production was impaired in 
both families since the affected genes disrupted the Dectin-1/Syk-CARD9 signaling 
pathway. 
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1.3.3 CMC – IL-17F and IL-17RA mutations 
Important “proof of concept” confirmation of the crucial role of IL-17 in protection 
against mucocutaneous candidiasis was provided by the demonstration that mutations of 
the IL-17 receptor (IL-17RA) and cytokine IL-17F (IL-17F) genes were associated with 
CMC [58]. In a consanguineous family, a child with CMC was found to display AR 
complete IL-17RA deficiency. His leukocytes and fibroblasts did not respond to IL-17A 
or IL-17F homodimers, or to IL-17A/F heterodimers. Four patients from another family 
were shown to harbour dominate-negative mutations in the IL-17F gene. Mutated 
IL-17F-containing homodimers and heterodimers were secreted in normal amounts but 
were not biologically active, as they were unable to bind to the IL-17 receptor. Morbid 
mutations in IL17RA and IL17F demonstrated that CMC could be directly caused by 
inborn errors of IL-17 immunity. 
 
1.3.4. CMC – IL-12RB1 mutations 
Some patients with deficiency of the IL-12/IL-23 signaling pathway are susceptible to 
mycobacteria (MSMD). A recent large survey of 141 MSMD patients found that 23% of 
patients had associated mild CMC, usually manifesting as recurrent oral thrush [59]. 
These patients have an underlying IL-12β1 deficiency (the most common form of 
MSMD) affecting the β1 chain for the common IL-12/IL-23 receptor. Mutations in 
IL-12β1 result in impaired IL-23 signaling and a low proportion of IL-17A-producing T 
cells in the circulation, which is likely the explanation of their susceptibility to CMC 
[60]. 
 
1.3.5 APECED/APS1 – AIRE mutations 
APECED/APS1 is a rare autosomal recessive syndrome characterized by multiple 
autoimmune polyendocrinopathies, such as hypoparathyroidism and adrenal failure. 
Intriguingly, up to 90% of APECED patients develop early-onset CMC. The genetic 
etiology of APECED was identified with mutations in the autoimmune regulator 
(AIRE)-encoding gene [61]. AIRE governs a T-cell tolerance pathway, by inducing the 
production, in the thymus and peripheral lymphoid organs, of transcripts encoding 
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proteins normally present in various peripheral tissues, this triggers the deletion of 
autoreactive T cells. Human AIRE deficiency therefore results in organ-specific 
autoimmunity disease. The etiology of the chronic candidiasis seen in these patients was 
baffling, until Puel et al. and Kisand et al. demonstrated high titers of neutralizing 
anticytokine autoantibodies, against IL-17A, IL-17F and IL-22. This provided an 
explanation for their susceptibility to CMC and a link to the underlying autoimmunity 
[62, 63]. 
 
1.3.6 CMC – MST1/STK4 mutations 
Another PID associated with CMC is deficiency of the MST1/serine threonine kinase 4 
(MST1/STK4) gene controlling human cell growth and apoptosis. The affected 
individuals also suffered from recurrent bacterial and viral infections, cutaneous warts 
and skin abscesses [64, 65]. The underlying mechanism of MST1/STK4 mutations 
leading to CMC is unclear. 
 
1.3.7 CMC – ACT1 mutations 
Mutations in the adaptor molecule ACT1 have been very recently reported in two 
siblings with CMC [66]. This mutation impairs the homotypic interaction of ACT1 with 
IL-17 receptors abolishing the response to IL-17A and IL-17F in fibroblasts and to 
IL-17E in leukocytes. The selectively abolished IL-17 responses are likely responsible 
for the susceptibility to CMC. 
 
1.3.8 CMC – Gain-of-function-STAT1 mutations 
In 14 patients from five families with AD-CMC, Van de Veerdonk FL et al. firstly 
revealed heterozygous mutations in the coiled-coil domain (CCD) of STAT1 [67]. Liu et 
al. [68] and Smeekens et al. [69] subsequently elucidated the molecular mechanisms 
manifesting as gain-of-function (GOF), as opposed to the previously reported 
loss-of-function (LOF) mutations underlying susceptibility to mycobacterial and/or viral 
diseases [70]. Takezaki et al. recently identified the first GOF mutation in DNA-binding 
domain (DBD) of STAT1 in patients presenting with CMC [71]. Up to date, numbers of 
GOF-STAT1 mutations have been found in over half of CMC patients [67-69, 71-74]. 
 10 
IL-17-producing T cell development is impaired in these patients [68, 71, 75], probably 
due to enhanced STAT1-dependent cellular responses to Th-17 cells repressors, such as 
IFN-γ, IFN-α/β and IL-27 [68]. However, the underlying mechanisms of GOF-STAT1 
mutations associated with impaired IL-17 production in the largest group of CMC have 
not yet been fully understood. 
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Figure 1.2 Genetic defects associated with Chronic Mucocutaneous Candidiasis. 
Known deficiencies associated with CMC are shown in red, including Dectin-1, 
CARD9 (caspase recruitment domain-containing protein 9), IL-12Rβ1 (IL-12 receptor 
β1), Tyk2 (tyrosine kinase 2), DOCK8 (dedicator of cytokinesis 8), STAT3 (signal 
transducer and activator of transcription 3), IL-17F, IL-17RA (IL-17 receptor A), AIRE 
(autoimmune regulator gene), ACT1, MST1 (also known as the serine threonine kinase 
4 (STK4)) and gain-of-function (GOF)-STAT1. 
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1.4 Signal transducer and activator of transcription signaling 
The heterozygous negative mutations of STAT3 and the GOF-STAT1 mutations 
mentioned above responsible for CMC are both affecting the latent cytoplasmic 
transcription factors – STAT proteins. Therefore, understanding the STAT signalling 
activation and function may provide better insight of the disease-causing mechanisms of 
CMC.  
Seven members of the STAT family have been identified including STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b, and STAT6. Transduction signals for STAT proteins 
(Fig 1.3a) originate from cytokines or growth factors binding to their cognate receptors 
on the cell surface, which initiate a series of tyrosine phosphorylation events carried out 
by members of the Janus kinases (JAKs). Following tyrosine phosphorylation, different 
STAT proteins homodimerize or heterodimerize, this alters the conformation of the 
STAT molecules and provides them with new properties. The activated STAT dimers 
gain the ability to bind import carriers that mediate their transport into the nucleus, 
where they bind to specific DNA sequences in gene promoters and lead to the induction 
of cytokine-responsive genes [76, 77]. After termination of the signal, STATs are 
dephosphorylated by phosphatases and translocated back to the cytoplasm from the 
nucleus. Typically, cytokine-induced transcription is a transient process, lasting only 
minutes to hours. STATs have been shown to play a role in cell growth and 
differentiation, proliferation, cell survival and apoptosis [78], however, genetic 
deficiency studies in humans have highlighted STATs specific functions in the control of 
various immune responses [79]. 
 
1.4.1 STAT structure, function and regulation 
STAT structure: All STAT proteins share a similar structural arrangement of functional 
motifs (Fig 1.3b), including the amino-terminal domain (NTD), the coiled-coil domain 
(CCD), the central DNA binding domain (DBD), the linker domain (LD) and the Src 
homology 2 (SH2) domain [78]. In contrast, the carboxy-terminal including the tail 
segment (TS) and transactivation domain (TAD) is quite divergent and associated with 
STAT specificity.  
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Structure associated function: The function of various domains of STATs has been 
extensively studied. NTD is involved in dimerization and tetramerization [80]. The 
CCD has considerable potential for involvement in protein-protein interactions and 
plays a key role in the dimerization of unphosphorylated STAT proteins and binding of 
nuclear phosphatases leading to STAT dephosphorylation [73, 81]. DBD defines the 
DNA-binding specificity and mediation of distinct signals for specific ligands. SH2 has 
been reported to mediate specific interaction between STAT-receptor, STAT-JAK and 
STAT-STAT [82]. Tyrosine residue in TS and serine residues in TAD are the two 
phosphorylation sites of STAT proteins. 
a
b
 
Figure 1.3 STAT signaling and structure [83]. 
a. In response to cytokine stimulation, STAT proteins become rapidly tyrosine 
phosphorylated, which allows them to dimerize, translocate to nucleus, where 
phosphorylated-STATs bind to DNA at their specific promoter sites thus regulating gene 
expression. 
b. Structure of STAT proteins, including amino-terminal domain (NTD), coiled-coil 
domain (CCD), DNA binding domain (DBD), Linker domain (LD), Src homology 2 
(SH2) and transactivation domains (TAD). 
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Regulation of STAT: The duration and magnitude of STAT activation is critically 
regulated by a number of different mechanisms at the cytoplasmic and nuclear levels, 
which together ensure that STAT proteins function in a strictly controlled manner in 
normal cells. These include the cytoplasmic and/or nuclear protein tyrosine 
phosphatases (PTP), protein inhibitors of activated STAT proteins (PIAS) and 
suppressor of cytokine-signaling proteins (SOCS) [80]. In the past several years, 
significant progress has been made in understanding of STAT acetylation and its role in 
modulating STAT activities, which relies heavily on the balance between histone 
deacetylases (HDACs) and histone acetyltransferases (HATs) [84]. 
 
1.4.2 STAT1 signaling and IFNs production 
STAT1 is the founder member of seven mammalian STATs which plays an essential role 
in IFN-mediated biological responses [78]. IFNs are cytokines that are crucial in host 
defense against mycobacterial and viral pathogens [79]. Mammalian type I IFNs 
(IFN-α/β) are produced by many cell types and confer antiviral activities on them, while 
type II IFN (IFN-γ) is produced mainly by T lymphocytes and natural killer cells and 
elicits broad effects, particularly on cells of the immune system. The transmission of 
both type I IFNs and IFN-γ signals are dependent on the activation of STAT1. It has 
been well recognized that IFN-α/β signals through STAT1/STAT2 heterodimers, while 
IFN-γ signals through STAT1 homodimers [85]. In the nucleus, the STAT1 homodimers 
dissociate from the import carrier and bind to specific DNA target sites such as 
IFN-γ-activation site (GAS) which is present in the promoters of certain IFN-stimulated 
genes (ISGs). STAT1/2 heterodimers, however, combine with IFN response factor 
(IRF)9 to form IFN stimulated gene factor (ISGF)3 which binds to the IFN-stimulated 
response element (ISRE) and induces responsive gene transcription including IRF1 and 
CXC-motif chemokine ligand (CXCL)10 genes. Although mechanism of activation and 
transcriptional regulation of STAT1 have been established, post-transcriptional 
regulation of STAT1 expression in not fully understood.  
 
1.4.3 STAT3 signaling and IL-17 production 
Cytokines that promote IL-17 production include IL-1, TGF-β, IL-6, IL-21 and IL-23 
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[86]. The last three cytokines transduce their signals through activation of STAT3. 
Although STAT3 is activated by a large number of cytokines and has crucial functions 
in various tissues, T cell-specific deletion of STAT3 mainly affects the expression of 
IL-17 and IL-22 [87]. Conversely, increased STAT3 activation, through the deletion of 
its negative regulator SOCS3, results in increased numbers of Th-17 cells [88]. The 
requirement for STAT3 in human IL-17 production was unraveled in patients with HIES 
(as described above). The impairment of STAT3 signaling and consequently attenuated 
Th-17 generation may explain these patients’ inability to clear bacterial and fungal 
infections. Chromatin immunoprecipitation-sequencing (ChIP-Seq) and transcriptional 
profiling have identified multiple genes that are direct targets of STAT3 in T cells 
including IL-17 and IL-22 genes [86], These two genes are crucial for Th-17 
cell-mediated homeostasis and epithelial barrier function [89]. Furthermore, STAT3 
directly binds to and regulates expression of several major transcription factors that 
drive Th-17 cell differentiation, including the gene encoding RORγt (RORc in humans) 
[86]. In addition, STAT3 regulates the effect of IL-23 as well as IL-6 mediated 
downstream signaling of these cytokine receptor complex [90]. 
 
1.5 Hypothesis and Aim 
 
1.5.1 Hypothesis 
As described above, mutations in PID patients with CMC mapped out the fungal 
immunity pathway, confirming the importance of the STAT3/Th-17 cytokine axis in 
host defense against Candida infections (Fig 1.2). However, the GOF-STAT1 mutations 
are not themselves on the fungal immune pathway according to current understanding. 
STAT1 and STAT3 are thought to play opposite roles in most cell types, although the 
underlying mechanisms are still a matter of speculation and presumably includes altered 
nuclear transport, competition for common receptor docking sites and/or formation of 
STAT1/STAT3 heterodimers [91]. As Th-17 cytokine production is highly dependent on 
STAT3 signaling, it is likely that GOF-STAT1 mutations interfere with this pathway 
thus reducing downstream IL-17 production which impairs fungal immunity leading to 
CMC.  
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1.5.2 Aims 
The present study was carried out to investigate how GOF-STAT1 mutations affect the 
STAT3 signaling pathway by assessing STAT3 activation/phosphorylation, nuclear 
translocation, DNA-binding, gene expression, cytokine production and whether IL-17 
signaling defects in CMC can be epigenetically modified. 
 
Therefore the scope of this thesis: 
 
 How do GOF-STAT1 mutations affect STAT1 activation and gene transcription? 
(see Chapter 3) 
 
 How do GOF-STAT1 mutations interfere with STAT3 activation and gene 
transcription? (see Chapter 4) 
 
 Does inhibition of STAT1 modify gene transcription and improve low 
Th-17-mediated cytokine production in cells bearing GOF-STAT1 mutations? (see 
Chapter 5) 
 
 Can modification of acetylation modulate gene transcription and rescue low 
Th-17-related cytokine production in cells with GOF-STAT1 mutations? (see 
Chapter 6) 
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CHAPTER 2 SUBJECTS, MATERIALS AND METHODS 
 
2.1 Subjects 
2.1.1 Ethical considerations and informed consent 
All of the work described in this thesis which involved samples obtained from CMC 
patients harbouring GOF-STAT1 mutations and healthy volunteers had been approved 
by Newcastle and North Tyneside Local Research Ethics Committee (Reference No: 
NAIRB-DL-01 and Great North Biobank – R&D Reference No: 5458/10/H0906/22). 
Patient-identifiable data were coded and kept securely in a locked office and locked 
filing cabinet. Signed informed consent from patients and volunteers was obtained 
following distribution of information sheets prior to clinic visit and verbal explanations 
prior to signing.  
 
2.1.2 CMC patients with GOF-STAT1 mutations 
AD-CMC patients involved in this study all had confirmed GOF-STAT1 mutations 
affecting the CCD (Appendix Table 8.1). Mutations were identified by using an 
array-based sequence-capture assay, followed by next-generation sequencing carried out 
in Radboud University, Nijmegen or in the Human Genetics Laboratory of the Centre 
for Life, Newcastle University. 
 
2.1.3 Healthy volunteers 
Healthy volunteers, all of whom gave informed consent, were recruited from the 
Musculoskeletal Research Group, Newcastle University. Additionally, healthy blood 
donor buffy-coat cones were collected from the National Blood Service, following 
separation of red blood cells for transfusion purposes. 
 
2.2 Materials 
Chemicals and biochemicals used for this study are commercially available grade 
reagents and listed in Appendix Tables 8.2 and 8.3. In addition, details of the antibodies, 
cytokines, oligonucleotides, primers and small interfering RNAs (siRNA) used for the 
 17 
research are listed in Tables 8.4 - 8.8 as shown in Appendix. 
 
2.3 Methods 
2.3.1 Cell culture and treatment 
For the purposes of this research, human peripheral blood mononuclear cells (PBMCs) 
and immortalized (Epstein-Barr virus – EBV transformed) B cell lines (because of 
limited availability of patient blood samples) from CMC patients with GOF-STAT1 
mutations and healthy volunteers were used. Cells were stimulated ex-vivo by 
incubation with multiple cytokines or treated in addition of chemical drugs. 
 
PBMC or CD4
+
 T cell isolation and cytokine stimulation: PBMCs or CD4
+
 T cells 
were isolated from either fresh peripheral blood samples or buffy-coat cones by use of 
Lymphoprep density gradient centrifugation. Whole blood was diluted 1:2 with HBSS 
(Lonza), buffy-coat cone was diluted within 50 ml HBSS, then layered onto 
Lymphoprep (Axis-Shield Diag) with 3:1 dilution and centrifuged at 800 x g for 20 
minutes at room temperature. RosetteSep human CD4
+
 T cell enrichment cocktail 
(StemCell Tech) was mixed with diluted cone buffy-coat (75 μl per ml) before being 
layered for density centrifugation. PBMCs or CD4
+
 T cells were collected from the 
interface. Cells were washed twice with HBSS containing 2% FCS (Lonza) 600 x g for 
7 minutes at 4
o
C then 250 x g for 7 minutes at 4
o
C to remove platelets. Cells were 
counted using a Burker-Turk haemocytometer and cultured in RPMI-1640 medium 
(Sigma) containing 2 mM L-glutamine (Sigma), 100 IU/ml penicillin and 100 μg/ml 
streptomycin (Sigma), at 37
o
C in a humidified 5% CO2 incubator.  
Cytokine stimulation was performed in 24-well plates with serum-free RPMI-1640 
medium. Cells (3x10
6
/ml, 1 ml per well) were stimulated with multiple cytokines 
(Appendix Table 8.5). Cytokine stimulation time and doses were described in Table 2.1. 
For IL-23 and IL-12 stimulation, cells were initially cultured with PHA (Sigma) and 
IL-2 (Novartis) in IMDM (Sigma) containing 10% serum replacement (Gibco) for 3 
days followed by incubation with IL-23 or IL-12 as indicated time periods. Stimulation 
was stopped by adding ice-cold 1x PBS.  
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Table 2.1 Cytokines stimulation time and doses. 
Cytokine Final Concentration Stimulation Time 
(for WB) 
Stimulation Time 
(for PCR) 
IFN-γ 1x103 IU/m 30 minutes  
IFN-α 1x103 IU/m 30 minutes 4 hours 
IL-27 50 ng/ml 30 minutes 4 hours 
IL-21 50 ng/ml 15 minutes 4 hours 
IL-6 50 ng/ml 15 minutes  
IL-23 100 ng/ml 30 minutes 4 hours 
IL-12 20 ng/ml 20 minutes 4 hours 
PHA 2 μg/ml 3 days 3 days 
IL-2 40 IU/ml 3 days 3 days 
 
EBV immortalization and cytokine stimulation: PBMCs (5-10x10
6
 cells pellet) was 
infected with 1 ml EBV supernatant (previously produced by culturing an EBV infected 
marmoset B95-8 cell line (kind gift of Professor John Kirby, Newcastle University, and 
stored at -80
o
C) in a 7 ml falcon round bottom tube with cap and incubated in beaker 
with warm water for 1 hour at 37
o
C, 5% CO2. After this, cyclosporine-A (CysA) 
(Sandoz) was added at a final concentration of 1 μg/ml to prevent generation of 
EBV-specific T suppressor cells (10 μl of an oil-based CysA was very slowly aspirated 
and transferred into 490 μl absolute alcohol in a bijou, then added to 4.5 ml of 
RPMI-1640 without FBS; 10 μl of this solution was then added to the 1 ml EBV 
supernatant and cell pellet). PBMCs with EBV supernatant were incubated for a further 
24 hours at 37
o
C, 5% CO2 and transferred into a well in a 24-well plate containing 1 ml 
RPMI-1640 with 10% FCS and 10 μl CysA (final concentration 1 μg/ml) prepared 
previously. EBV transformation was monitored daily over a couple of weeks.  
Before stimulation, EBV transformed cells were starved in serum-free RPMI-1640 
medium for 4 hours. Cells (5x10
6
/ml, 1 ml per well) were then stimulated in 24-well 
plates as described in Table 2.1. The stimulation was stopped by adding ice-cold 1xPBS. 
 
Chemical treatment: Trichostatin A (TSA; Sigma), an HDAC inhibitor, was used at 100 
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ng/ml and added to cell medium together with cytokines, whereas Fludarabine (a 
STAT1 inhibitor, Selleckchem) was added into cell culture 1 hour before stimulation at a 
final concentration 100 μg/ml. Staurosporine, a phospho-kinase inhibitor, was used to 
prevent phosphorylation of STAT proteins which was assessed by stimulating EBV 
transformed cells with 1x10
3 
IU/ml or 0.5x10
3 
IU/ml IFN-α for 30 minutes and adding 
Staurosporine (Calbiochem) at 1 μM in RPMI-1640 for a further 15, 30, 60 minutes. 
Pervanadate, a phosphatase inhibitor, was used to inhibit dephosphorylation of STAT 
proteins, mimicking the gain-of-function mutation. It was prepared by mixing 
orthovanadate (Sigma) with H2O2 for 15 minutes at 22
o
C. Cells were treated with 
Pervanadate (0.8 mM orthovanadate and 0.2 mM H2O2) 5 minutes before stimulation. 
Cells were then stimulated with IFN-α for 30 minutes. The stimulation was stopped by 
adding ice-cold 1x PBS. 
 
Candida albican stimulation: Freeze-dried Candida albicans (ATCC, 18804) were 
rehydrated by adding 6 ml sterile distilled water. The suspension was shook vigorously 
to dissolve and left at room temperature overnight without disturbing. Rehydrated C. 
alibcans were frozen down as 200 μl aliquots at -20oC. When required, C. alibcans were 
thawed and cultured with Yeast Nitrogen Base (YNB, BD) liquid medium containing 
0.5% w/v D-Glucose (Sigma) and 10% FCS in a 37
o
C, 5% CO2 incubator overnight, 
followed by centrifuging at 800 x g for 10 minutes. The C. alibcans pellet was then 
collected and diluted (1:15x10
3
) for cell stimulation in the presence of Amphotericin B 
(final concentration 2.5 μg/ml, Sigma) for 5 days. Supernatant was collected and stored 
at -20
o
C before being used for cytokine production measurements. 
 
Cell Viability Assays: CellTiter 96
®
 AQueous Non-Radioactive Cell Proliferation Assay 
(Promega) was used in this study as a colorimetric method for determining cell viability. 
The method is based on in vivo reduction by metabolically active cells of a tetrazolium 
compound 
(MTS=3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H
-tetrazolium) to a coloured formazan, with maximal absorbance at 490 nm, that is 
released into culture medium. Assays were performed by adding a small amount of the 
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solution directly to culture wells (1:4), incubating for 3 hours and then recording the 
absorbance at 490 nm with a 96-well plate reader. The quantity of formazan product, as 
measured by the absorbance at 490 nm, is directly proportional to the number of living 
cells in culture. 
 
2.3.2 Western Blotting 
Western blotting (WB, also called immunoblotting because an antibody is used to 
specifically detect its antigen) is a routine technique for protein analysis. It uses gel 
electrophoresis to separate native proteins by 3-D structure or denatured proteins by the 
length of the polypeptide. The proteins are then transferred to a polyvinylidene fluoride 
(PVDF) membrane, where they are recognized with antibodies specific to target protein. 
WB was performed in this study for the assessment of STAT proteins phosphorylation, 
subcellular localization and siRNA-mediated gene silencing efficiency. 
 
Extraction of cellular fraction proteins: Cytoplasmic and nuclear proteins were 
extracted by using NE-PER Nuclear and Cytoplasmic Extraction Kits (Thermo 
Scientific) according to manufacturer’s instructions. Briefly, addition of the first two 
reagents to a cell pellet causes cell membrane disruption and release of cytoplasmic 
contents. After recovering the intact nuclei from the cytoplasmic extract by 
centrifugation, the proteins are extracted out of the nuclei with the third reagent. 
Cellular fraction proteins were snap-frozen on dry ice and stored at -80
o
C. 
 
Extraction of whole cell lysate: Following cytokine or chemical treatment, cells were 
collected and washed once in ice-cold 1x PBS and pelleted at 13,000 x g for 1 minute at 
4
o
C, to remove any residual phenol red from the medium. Following careful removal of 
PBS to leave a dry cell pellet, 30 μl of whole cell lysis buffer (Appendix Table 8.9) per 
million cells was added to the cell pellet and incubated on ice for 30 minutes. The cells 
were then pelleted at 13,000 x g for 8 minutes at 4˚C. Lysates were then carefully 
removed from the pellet and transferred to pre-cooled eppendorfs and stored at -80˚C.  
 
Bradford assay for protein quantification: To measure the protein concentration in an 
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extract, the dye-binding assay Bradford (Bradford Assay) was performed. A standard 
curve was generated by diluting Bovine Serum Albumin (BSA) stock solution (2 mg/ml 
BSA protein standards (Thermo Scientific)) in the lysis buffer used for extraction. 
Extracted proteins were diluted in lysis buffer and 300 μl of Bradford Ultra (Expedeon) 
was added to each sample. Following 5 minutes incubation, protein absorbance was 
read at 595 nm using a Tecan sunrise microplate absorbance reader. A standard curve 
was plotted and used to determine the protein concentration of test samples. 
 
Immunoblotting: For immunoblotting, equal amounts of protein (1:5 dilution with 5x 
Sample buffer) were subjected to Sodium Dodecyl Sulfate – Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) using 10% polyacrylamide gels (consist of a lower 10% 
acrylamide separating gel and a upper stacking gel) at a constant voltage of 100 V in the 
running buffer. After SDS-PAGE, proteins were transferred to a polyvinylidene fluoride 
(PVDF) membrane by using the iBlot
TM
 Gel Transfer Device (Invitrogen) with iBlot® 
Transfer Stack, PVDF Regular package (Invitrogen). The membrane was then blocked 
with 5% (w/v) milk powder in Tris-Buffered Saline-Tween (TBS/T) buffer for 1 hour at 
room temperature followed by incubation overnight at 4
o
C with antibodies (Appendix 
Table 8.4). The blots were then washed three times with TBS/T and incubated with 
HRP-conjugated goat anti-rabbit (Dako) at a dilution of 1:2,000 in 5% (w/v) milk 
powder in TBS/T for 1 hour at room temperature. After washing the blots three times 
with TBS/T, the blots where developed with ECL according to the manufacturer’s 
instructions (GE Healthcare). All the buffers used for WB were described in Appendix 
Table 8.9. 
 
2.3.3 Electrophoretic mobility shift assay 
STAT protein DNA-binding was evaluated using electrophoretic mobility shift assay 
(EMSA). EMSA is based on the observation that complexes of protein and DNA 
migrate through a nondenaturing polyacrylamide gel more slowly than free 
double-stranded oligonucleotides. This gel shift assay is performed by incubating 
proteins with end-labeled double-stranded DNA oligonucleotides containing the 
putative binding site and nonspecific DNA competitor, usually a polyanion polymer 
 22 
such as poly (dI-dC). The specificity of an observed DNA-binding reaction can be 
evaluated using competition assays in which an excess of unlabeled probe is added 
together with the labeled probe. In addition to a labeled probe, specific antibodies can 
be added to the gel shift reaction. If the protein that forms the complex is recognized by 
the antibody, the antibody can either block complex formation, or it can form an 
antibody-protein-DNA complex, resulting in a further reduction in the mobility of the 
protein-DNA complex (supershift). 
 
Nuclear protein extraction: A two-step process was used to obtain crude nuclear extract 
with homemade buffers (described in Appendix Table 8.10). Low salt detergent 
hypotonic buffer was used to perforate the plasma membrane and release cytoplasmic 
contents, leaving nuclear membranes intact. High salt solution was then used to leach 
out the nuclear proteins. Cells were treated as described then collected and washed once 
in ice-cold 1x PBS and pelleted at 13,000 x g for 1 minute at 4
o
C. Cell pellet (20x10
6 
cells) was resuspended in 1 ml of hypotonic buffer and incubated on ice for 15 minutes. 
Cells were pelleted as before and the supernatant containing cytosolic protein was 
discarded. The pellet was resuspended in ice-cold hypotonic buffer supplemented with 
0.25 M sucrose (in order to fractionate the nuclei). Cells were centrifuged and the pellet 
was resuspended in 80 μl high salt buffer. Following a 30 minutes incubation on ice, 
cells were centrifuged for the final time at 10,000 x g for 2 minutes at 4
o
C and the 
supernatant containing nuclear protein was snap-frozen on dry ice and stored at -80
o
C. 
 
Protein-DNA binding reaction and electrophoresis: Labelled or unlabelled DNA 
oligonucleotides (Appendix Table 8.6) were resuspended in dH2O (Sigma) to a 
concentration of 100 pmol/μl. Oligonucleotides were heated to 95oC for 5 minutes in 
annealing buffer at the final concentration of 10 pmol/μl and then allowed to cool to 
room temperature for 4 hours to enable annealing of probes. The native acrylamide gel 
was prepared the day before the EMSA reaction and left to set at 4
o
C overnight. The gel 
was pre-run for 30 minutes in running buffer prior to the loading of samples in order to 
remove any traces of Ammonium Persulphate (APS; Sigma), to equilibrate ions within 
the running buffer and to ensure constant gel temperature. The binding conditions were 
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prepared for STAT proteins and incubated at room temperature for 20 minutes in the 
dark. When using unlabelled competitor oligonucleotides or antibodies (Appendix Table 
8.4) to confirm the binding of candidates, these were added 15 minutes prior to the 
addition of fluorescently labelled oligonucleotide. Orange G loading dye (from EMSA 
kit, LiCor Bioscience) was then added (1x final concentration) and samples were loaded 
onto the gel. Electrophoresis was performed at 100 V at 4
o
C in the dark for 
approximately 4 hours, or until the dye front has reached the end of the gel. 
Visualisation was carried out using the LiCor Odyssey Infrared Imager (LiCor 
Bioscience). All the buffers and binding conditions used for EMSA were described in 
Appendix Table 8.10. 
 
2.3.4 Flow cytometry - phosflow cell signaling 
Flow cytometry measures the optical properties of single cells as they pass through the 
functional core of the instrument. When cells are stained with fluorescence markers, it 
can be used to measure the expression level of multiple surface and intracellular 
proteins of individual cells in a population. BD Phosflow technology was performed in 
this study to reveal intracellular staining of STAT1 phosphorylation events. 
Following cytokine stimulation, EBV cells were fixed immediately by adding 10x 
volumes of pre-warmed 1x Lyse/Fix Buffer (BD). Following incubation at 37
o
C for 10 
minutes, cells were pelleted by centrifugation at 600 x g for 8 minutes at room 
temperature. Pellet was resuspended by vortexing, followed by permeabilization with 1 
ml (per 1-10x10
6
 cells) of Phosflow Perm buffer III (BD) and incubated at -80
o
C in the 
dark overnight. Cells were then washed twice in staining buffer (PBS containing 2% 
FCS) at 600 x g for 8 minutes at 4
o
C. Pellet was resuspended in 100 μl staining buffer 
and 10 μl of Alexa Fluor® 647 STAT1 (pY701) antibody (BD) for 1 hour incubation at 
room temperature in the dark. Prior to flow cytometric analysis, cells were washed once 
in staining buffer and then resuspended in 300 μl staining buffer. 
 
2.3.5 Quantitative real time-polymerase chain reaction  
Gene expression analysis was determined using a Taqman primer-probe based approach 
of quantitative real time-polymerase chain reaction (qRT-PCR). The probe is 
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constructed containing a reporter fluorescent dye on the 5’ end and a quencher dye on 
the 3’ end. During DNA amplification, the reporter dye is released from the quencher 
and emits fluorescence to enable the detection of specific PCR product when the 
polymerase enzyme cleaves the probe from DNA. 
 
RNA isolation: Total RNA was extracted from cells using TRI Reagent (Sigma). Cells 
(2-5x10
6
) following cytokines treatment were
 
collected and pelleted. Each sample was 
homogenised in 1 ml TRI Reagent. The homogenate was then incubated at room 
temperature for 5 minutes to ensure complete dissociation of nucleoprotein complexes. 
Chloroform (0.2 ml) was added and the components mixed. After 3 minutes incubation 
at room temperature, samples were centrifuged at 13,000 x g for 15 minutes at 4
o
C. The 
aqueous phase containing the RNA was collected. RNA was then precipitated with 0.5 
ml of isopropanol by incubating the mixture for 10 minutes at room temperature. RNA 
was pelleted by centrifugation at 13,000 x g for 10 minutes at 4
o
C, and washed with 
75% ethanol (7500 x g for 5 minutes at 4
o
C). Finally, the RNA was resuspended in 20 μl 
RNase- and DNase-free H2O (Sigma) and stored at -80
o
C. 
 
Complementary DNA reverse transcription: For reverse transcription, 0.5 μg RNA 
sample was mixed with 2 μg Random hexamer pd (N)6 (GE Healthcare) and H2O 
(Sigma) up to 9 μl. Samples were incubated at 70oC for 10 minutes. Following this, 
pre-prepared buffer containing 0.5 μl of 10 mM dNTPs (Bioline), 4 μl of 5x first stand 
buffer, 2 μl of 0.1 M Dithiothreitol (DTT), 0.5 μl (100 units) of Superscript II 
(Invitrogen) and 0.5 μl of H2O was added to each tube and incubated at 42
o
C for 1 hour. 
The stable complementary DNA (cDNA) was then stored at -20
o
C for further use. 
 
Gene expression analysis by qRT-PCR: Gene expression analysis was performed with 
TaqMan Gene Expression Assays (Applied Biosystems, ABI) which consists of a pair of 
unlabeled PCR primers and a TaqMan probe with a FAM dye label on the 5’ end and a 
nonfluorescent quencher on the 3’ end (listed in Appendix Table 8.7). PCR reactions (10 
μl) were prepared containing 1x gene expression assay (primer and probe mix), 1x 
TaqMan Gene Expression Master mixture (Life Technologies) and cDNA (diluted 1:5 
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for RORc, IL-22, IL-17, diluted 1:10000 for 18S, and diluted 1:10 for all other genes). 
The Prism 7900HT sequence detection system (ABI) was used for PCR cycling (50
o
C 
for 2 minutes, 95
o
C for 10 minutes and 40 cycles of 95
o
C for 15 seconds and 60
o
C for 1 
minute) and detection. For analysis, gene expression was normalised to the house 
keeping gene 18S rRNA. Data were expressed in the 2
-∆Ct
 format, where ∆Ct = Ct 
(target) – Ct (18s). 
 
2.3.6 siRNA-mediated gene silencing 
Short/small interfering RNA (siRNA) is a widely used approach to effectively knock 
down gene expression and to study protein function in a wide range of cell types. In 
order to assess the roles of certain transcription factors in the regulation of 
STAT-induced gene expression, gene expression was silenced using siRNA Accell 
SMARTpool (Thermo Scientific) targeting of HDAC1, HDAC2 or HDAC3, or a 
non-targeting sequence as a negative control in PBMCs or EBV cells. Gene silencing 
was performed in 24-well plates, cells (3x10
6
/ml for PBMCs, 5x10
6
/ml for EBV cells) 
were incubated with 1 μM final concentration of Accell siRNA (Appendix Table 8.8) in 
Accell delivery medium (Thermo Scientific) for 72 hours at 37
o
C in 5% CO2 incubator 
without serum replacement for the first 48 hours, after which 2.5% serum replacement 
was added into PBMC cultures but not EBV cells. For IL-23 stimulation, PHA and IL-2 
were added into the cell culture at the same time as cell transfection was performed. 
Cytokine stimulation was carried out after 72 hours transfection. To evaluate gene 
knockdown efficiency, longer incubation (96 hours transfection) was required for 
HDAC1, HDAC2 and HDAC3 protein expression assessment.  
 
2.3.7 Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assay was performed in this study to evaluate 
STAT3 DNA binding in vivo in cells from CMC patients with GOF-STAT1 mutations. 
ChIP assay is a powerful technique which can identify links between the genome and 
the proteome by monitoring transcription regulation through histone modification or 
transcription factor-DNA binding interactions. The strength of ChIP assays is their 
ability to capture a snapshot of specific protein-DNA interactions occurring in vivo. 
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Additionally, ChIP allows for measurement of relative changes in protein-DNA 
interaction levels using quantitative polymerase chain reaction (qPCR).  
 
Cross-linking: EBV cells were stimulated with IFN-α as described before. 
Formaldehyde (Sigma) was added to crosslink cells (～50x106 cells) at a final 
concentration of 1% and incubated at room temperature for 10 minutes. Glycine (Sigma) 
was added at a final concentration of 0.125 M to quench un-reacted formaldehyde. Cells 
were pelleted in a 15 ml falcon at 1300 x g at 4
o
C for 5 minutes. 
 
Lysis and sonication: After discarding the supernatant, the cell pellet was resuspended 
in 800 μl SDS cell lysis buffer (prepared as described in Appendix Table 8.11) 
containing 1x protease inhibitor cocktail II (Millipore) and incubated on ice for 30 
minutes. Sonication was carried out using a probe sonicator (Soniprep 150, MSE, UK), 
on ice, at 10 minutes for 10x 15 second intervals with 15 second rest periods. Sonicated 
lysates were then centrifuged at 1300 x g at 4
o
C for 5 minutes. 
 
Immunoprecipitation: Chromatin (100 μg) was diluted (1:10) with ChIP dilution buffer 
containing 1x protease inhibitor cocktail II and 30 μg of blocked Staphylococcus aureus 
(Staph A) membranes (Zysorbin from Invitrogen) and incubated with rotation at 4
o
C for 
30 minutes. The blocked Staph A membranes facilitate the antibody being coupled to a 
solid substrate. Following this incubation, samples were centrifuged at 2500 x g at 4
o
C 
for 5 minutes. Supernatant was removed and split into 2 tubes. Antibody (3 μg) either 
irrelevant or target-specific was used for each immunoprecipitation. Samples were then 
incubated overnight at 4
o
C with rotation. The following day, 50 μl Staph A was added 
into each sample and incubated for 60 minutes at 4
o
C, followed by 30 minutes at room 
temperature. Supernatant was removed by centrifugation at 6000 x g for 5 minutes, and 
the pellet then washed in low salt immune complex wash, high salt immune complex 
wash, lithium chloride complex wash and finally buffer TE, each for 5 minutes with 
rotation and the supernatant discarded. The pellet was resuspended in 500 μl ChIP 
elution buffer for further 20 minutes incubation with rotation at room temperature. All 
the buffers mentioned above were prepared as described in Appendix Table 8.11. 
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Following the final wash, supernatant was collected and 20 μl 5 M NaCl was added to 
each 500 μl samples. After an incubation at 65oC for 4 hours, 10 μl of 0.5 M EDTA, 2 μl 
of 1 M Tris-HCl (pH6.5) and 2 μg of proteinase K (Sigma) was added to each sample 
and incubated at 45
o
C for 1 hour. Following reversal of cross-linking, eluate was mixed 
with an equal amount of phenol and centrifuged at 13000 x g for 5 minutes. DNA 
purification was carried out using spin columns provided in the Gel Extraction kit 
(Qiagen) according to the manufacturer’s instructions.  
 
Polymerase chain reaction: DNA was amplified by PCR using human c-Fos promoters 
(F: 5’-CCACGCTTTGCACTGAATTA-3’; R: 5’-GAGAACATTCGCACCTGGTT-3’) 
located in the STAT3 region. Real time-PCR analysis was performed on an ABI 
7500HT sequence detection system. In brief, qPCRs comprised of 3 μl of 
immunoprecipitated DNA template, 0.5 μM forward and reverse primers, 6.5 μl of 
Jumpstart SYBR green master mixture (Sigma) in a total reaction volume of 13 μl. PCR 
was performed in triplicate. After the initial 5 seconds incubation at 95
o
C, qPCRs were 
carried out by 40 cycles of 95
o
C for 5 seconds, annealing at 57
o
C for 30 seconds, and 
extension at 72
o
C for 30 seconds and a final step of 95
o
C for 5 seconds. After each run, 
a dissociation curve was performed to ensure that no primer-dimers contaminated the 
quantification and that the product had the expected melting temperature. A signal 
intensity value for each sample was calculated from the average of the experiments. 
Average values of eluates were normalized to average values of inputs after subtracting 
the background control, and differences between samples calculated using the following 
equation: [1/(2, A)]x100.  
 
2.3.8 Enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assay (ELISA) is a biochemistry assay that uses a 
solid-phase enzyme immunoassay to detect the presence of a substance, usually an 
antigen, in a liquid or wet sample. It was employed in this study to evaluate STAT3 
DNA-binding and cytokine production in cell culture medium. 
 
TransAM STAT3 DNA binding: STAT3 DNA binding was evaluated by TransAM 
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STAT3 kit (Active Motif) according to manufacturer’s instructions. TransAM STAT3 is 
an ELISA-based kit, containing immobilized oligonucleotide (hSIE) containing a STAT 
consensus binding site (5’-TTCCCGGAA-3’). The activated STAT3 contained in 
nuclear extracts binds to this oligonucleotide. The primary antibody used to detect STAT 
recognizes an epitope on STAT3 that is accessible only when STAT3 is activated and 
bound to its target DNA. An HRP-conjugated secondary antibody provides a sensitive 
colorimetric readout that is easily quantified by spectrophotometry at 450 nm using a 
Tecan sunrise microplate absorbance reader.  
 
Cytokine production: Production of IL-17 and IL-22 cytokines in cell culture 
supernatant was measured by ELISA kit (eBioscience) according to manufacturer’s 
instruction using in-house ELISA buffers and microtiter plates.  
Production of IL-10 cytokine was detected in cell culture supernatant with buffers 
described in Appendix Table 8.12. IL-10 capture antibody (2 μg/ml; BD) was coated on 
to microtiter plates overnight at 4
o
C. After 1 hour blocking with blocking buffer, 50 μl 
of appropriately diluted samples in diluent buffer was added and incubated overnight at 
4
o
C. Standards (duplicates) and blanks were run with samples to ensure accuracy. After 
three washes with washing buffer, 50 μl of detection antibody (1 μg/ml, BD) was added 
to each well and incubated at room temperature for 1 hour. Following four washes, 50 
μl of ExtrAvidin-Peroxidase (Sigma) conjugate (1:1000 dilution) was added to each 
well and incubated for 30 minutes at room temperature. Substrate (50 μl) was added 
after five washes and incubated at room temperature until color developed. The reaction 
was stopped by adding 50 μl 3 M H2SO4 and the absorbance read at 490 nm using a 
Tecan sunrise microplate absorbance reader.  
 
2.3.9 Transfection of cell lines 
To evaluate transcriptional activity of STAT3 in CMC patients with gain-of-function 
STAT1 mutations, STAT3 Luciferase Assay (Cignal Reporter Assay, Qiagen) was 
performed in EBV transformed cells. Cell transfection efficiency was evaluated by 
comparing EBV cell line to SW1353 (SW) cell line (human chondrocytes, ATCC, 
HTB-94) with the positive control (40:1:1 mixture of constitutively expressing GPF, 
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constitutively expressing firefly luciferase, and constitutively expressing Renilla 
luciferase) from the Cignal Report Assay kit. SW cells were seeded at a density of 
7x10
4
/ml, 100 μl per well in a 96-well plate and serum-starved in DMEM (containing 
high glucose, 2 mM L-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin) for 24 
hours prior to transfection. EBV cells were cultured at a density of 5x10
6
/ml, 100 μl per 
well in a 96-well plate in RPMI-1640 serum-free medium. Optimization of cell 
transfection was performed with indicated amount of GFP (Cignal Reporter Assay, 
Qiagen) and Attractene Reagent (Qiagen) mixture for 48 hours transfection according to 
manufacturer’s instructions (Table 2.2). Transfection efficiency was observed by using 
Zeiss Inverted Microscope (Zeiss, Germany). 
 
Table 2.2 Pipetting scheme for optimizing cell transfection in a 96-well plate. 
Amount of DNA (μg) 
Volume of Attractene Reagent (μl) 
Final volume of diluted DNA (μl) 
0.1 
0.25 
50 
0.1 
0.375 
50 
0.1 
0.75 
50 
Amount of DNA (μg) 
Volume of Attractene Reagent (μl) 
Final volume of diluted DNA (μl) 
0.2 
0.5 
50 
0.2 
0.75 
50 
0.2 
1.5 
50 
Amount of DNA (μg) 
Volume of Attractene Reagent (μl) 
Final volume of diluted DNA (μl) 
0.3 
0.75 
50 
0.3 
1.125 
50 
0.3 
2.25 
50 
 
2.3.10 Statistical analysis 
Two statistical analyses were performed in this study. 
Mann Whitney (nonparametric) t test was used to compare groups between healthy 
controls and CMC patients in responses to different treatments (cytokines, fludarabine 
or TSA). Statistical analysis and plotting of data was performed using Prism 5.0 
software (GraphPad Software, USA). P values less than or equal to 0.05 were 
considered significant (*), P ≤ 0.01 highly significant (**). 
Estimation of the effects between different treatments was analyzed employing analysis 
of variance techniques using Version 21 of the SPSS statistical software system. Type 
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III sums of squares were used to adjust for imbalances in the number of experiments 
performed in each of the groups. Maximum likelihood estimates and 95% confidence 
intervals (CI) were calculated using a pooled estimate of the variability weighted by the 
number of observations in each group [92]. A generalized linear model allowed 
comparison of healthy controls and CMC patients, and estimation of the effects of 
fludarabine and TSA together with their interactions. Pairwise comparisons were 
performed using the somewhat conservative Bonferroni adjustment for multiplicity. 
Statistically significant differences between the treatment groups were presented as P ≤ 
0.05 significant (*), P ≤ 0.01 highly significant (**). 
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CHAPTER 3 GOF-STAT1 MUTATIONS ENHANCE STAT1 
ACTIVATION AND GENE TRANSCRIPTION 
 
3.1 Rationale 
Mutations underlying susceptibility to Candida infections in a large subgroup of 
AD-CMC patients has recently been identified in the STAT1 gene affecting CCD and 
DBD [67]. Mutations in STAT1 gene have previously been described albeit in other 
domains resulting in primary immune deficiencies of different clinical phenotypes. The 
heterozygous STAT1 loss-of-function mutant alleles with an AD inheritance confer 
susceptibility to mycobacterial disease [93]. The homozygous loss-of-function STAT1 
mutant alleles with an AR inheritance confer susceptibility to a broad range of bacterial 
and viral infections [94]. Between them, the recessive hypomorphic STAT1 
(homozygous and compound heterozygous) loss-of-function mutant alleles confer 
susceptibility to milder intramacrophagic bacterial and viral diseases [95]. 
In contrast, the STAT1 mutant alleles identified in AD-CMC are gain-of-function and 
lead to increased STAT1-dependent cellular responses [68]. It is not known how the 
enhanced STAT1 activation in AD-CMC leads to impaired Th-17 immunity and confers 
susceptibility to fungal infections which is the hallmark of this PID. In the present 
chapter, I present results confirming the enhanced STAT1 activation as a result of the 
gain-of-function mutations and investigate downstream effects on STAT1 function, 
specifically STAT1-dependent gene induction. 
 
3.2 Aims 
In the presence of GOF-STAT1 mutations:  
 Confirm enhanced STAT1 activation/phosphorylation 
 Investigate kinetics and mechanisms of STAT1 phosphorylation and 
dephosphorylation  
 Evaluate the effect on STAT1 DNA-binding activity  
 Determine downstream effect on STAT1-dependent gene induction   
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3.3 Results 
3.3.1 GOF-STAT1 mutations result in enhanced STAT1 phosphorylation  
To evaluate STAT1 activation, I compared STAT1 phosphorylation in AD-CMC patients 
to healthy controls. Upon stimulation with IFN-γ, IFN-α or IL-27, GOF-STAT1 mutants 
showed higher levels of STAT1 phosphorylation both in PBMCs and EBV transformed 
cells. Total STAT1 was expressed at equal levels, as shown by WB (Fig 3.1). 
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Figure 3.1 Increased STAT1 phosphorylation in cells of AD-CMC patients.  
Western blotting was performed on whole cell lysates of EBV transformed cells (A) and 
PBMCs (B) from 3 healthy controls (HC) and 2 CMC patients (CMC). Prior to lysing, 
cells were stimulated for 15 minutes with 50 ng/ml IL-6, IL-21, or 30 minutes with 
1x10
3
 IU/ml IFN-γ, IFN-α and 50 ng/ml IL-27. GAPDH was used as a loading control. 
Data shown are representative of at least 3 independent experiments. 
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3.3.2 Enhanced initial phosphorylation and impaired dephosphorylation of STAT1 
accounting for gain-of-function 
To understand the underlying mechanism involved in gain of function STAT1 activation, 
I assessed STAT1 dephosphorylation following IFN-α treatment. These mutations led to 
a delayed STAT1 dephosphorylation for up to 90 minutes, a time at which STAT1 
phosphorylation in healthy subjects had almost returned to baseline levels as shown by 
WB (Fig 3.2). Flow cytometry confirmed the delayed dephosphorylation of the mutant 
STAT1 by intracellular staining (Fig 3.3). 
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Figure 3.2 STAT1 mutants lead to impaired dephosphorylation. 
Dephosphorylation in EBV transformed cells from CMC patients (CMC) and healthy 
controls (HC) stimulated or not with IFN-α (1x103 IU/ml) for the indicated time periods. 
GAPDH was used as a loading control. Data shown are representative of 2 independent 
experiments. 
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Figure 3.3 STAT1 mutants result in delayed dephosphorylation. 
Dephosphorylation measured by means of flow cytometry in EBV transformed cells 
from CMC patients (CMC) and healthy controls (HC) stimulated with or without IFN-α 
(1x10
3
 IU/ml) for the indicated time periods. Results are representative of 2 independent 
experiments as mean fluorescence intensity (NS, non-stimulated). 
 
Hyper-phosphorylation of STAT1 could be mimicked in control cells by addition of 
pervanadate, a phosphatase inhibitor that prevents dephosphorylation and nuclear exit. 
Fig 3.4 demonstrated that addition of pervanadate increased STAT1 phosphorylation in 
control cells to levels seen in cells with the GOF-STAT1 mutations. 
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Figure 3.4 Blocking dephosphorylation mimics hyper-phosphorylation.  
WB of whole cell lysates extracted from EBV cells derived from a healthy control (HC) 
and an AD-CMC patient (CMC), in the absence or presence of the phosphatase inhibitor 
pervanadate for 5 minutes and then treated or not with IFN-α (1x103 IU/ml) for 30 
minutes. GAPDH was used as a loading control. Data shown are representative of 2 
independent experiments. 
 
Conversely, addition of staurosporine, a tyrosine kinase inhibitor reduced the initial 
level of phosphorylation for the GOF-STAT1, allowing the subsequent 
dephosphorylation to occur with similar kinetics to normal cells (Fig 3.5). A similar 
effect was achieved with suboptimal stimulation of cells with GOF-STAT1 mutations 
(Fig 3.6), which also led to lower levels of phosphorylation and normalization of 
dephosphorylation. These data demonstrated that STAT1 mutations resulted in a gain of 
STAT1 phosphorylation due to an impaired dephosphorylation as well as enhanced 
initial phosphorylation.  
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Figure 3.5 Limiting initial phosphorylation normalize dephosphorylation kinetics 
in cells with GOF-STAT1 mutations. 
GOF-STAT1 dephosphorylation of nuclear extracts (A) or whole cell lysates (B) was 
tested by WB in EBV cells from a healthy control (HC) and an AD-CMC patient (CMC). 
Cells were left unstimulated or stimulated with IFN-α (1x103 IU/ml) for 30 minutes, 
then incubated with or without 1 μM of the tyrosine kinase inhibitor staurosporine for 
15, 30, or 60 minutes. Histone H3 and GAPDH antibodies were used as the loading 
control for nuclear and whole cell extracts respectively. 
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Figure 3.6 Suboptimal stimulation and limiting phosphorylation normalize 
dephosphorylation kinetics in cells with GOF-STAT1. 
A. STAT1 dephosphorylation of whole cell lysates was tested by WB in EBV cells from 
a healthy control (HC) and an AD-CMC patient (CMC). Cells were left unstimulated or 
stimulated with IFN-α (0.5x103 IU/ml) for 30 minutes, then incubated with or without 1 
μM of the tyrosine kinase inhibitor staurosporine for 15, 30, or 60 minutes. GAPDH 
was used as a loading control. B. Kinetics of STAT1 dephosphorylation were studied by 
intracellular phospho-tyrosine 701 STAT1 staining in EBV cells from a healthy control 
(HC) and 2 AD-CMC patients (CMC) treated with IFN-α and staurosporine as described 
above. Results are presented as mean fluorescence intensity (NS, non-stimulated). 
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3.3.3 GOF-STAT1 mutations result in enhanced STAT1 DNA binding 
To determine STAT1 DNA binding in EBV transformed cells following IL-6, IL-21, 
IL-27, IFN-α or IFN-γ stimulation, I incubated nuclear extracts with a mutant human 
sis-inducible element (hSIE) probe (a STAT-consensus binding site element) and tested 
binding in EMSA. IFN-γ-, IFN-α- and IL-27-induced STAT1 homodimers, whilst 
IFN-α-induced STAT1/STAT3 heterodimers DNA-binding to the hSIE was stronger in 
cells from AD-CMC patients than in those from healthy controls (Fig 3.7). STAT protein 
DNA-binding specificity was confirmed by using unlabeled competitor or targeted 
antibodies (Fig 3.8).  
 
- IL-6    IFNγ IFNα IL-21    IL-27 - IL-6    IFNγ IFNα IL-21   IL-27
HC CMCa32
1
2
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Figure 3.7 GOF- STAT1 mutations lead to enhanced STAT1 DNA-binding. 
DNA binding was assessed using the hSIE probe and nuclear extracts from EBV 
transformed cells derived from a healthy control (HC) and an AD-CMC patient (CMC) 
following stimulation with IL-6, IL-21 (50 ng/ml) for 15 minutes, or IFN-α, IFN-γ 
(1x10
3
 IU/ml), IL-27 (50 ng/ml) for 30 minutes. Arrows indicate STAT1 and STAT3 
complexes binding to the probe: 1, STAT3 homodimers; 2, STAT3/STAT1 heterodimers; 
3, STAT1 homodimers. Results are representative of at least 3 independent experiments. 
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Figure 3.8 EMSA analyses investigating STAT protein binding to the hSIE probe.  
The EMSA reaction contained the labeled hSIE probe and nuclear extracts from normal 
EBV cells following stimulation with IL-21 (50 ng/ml) for 15 minutes, IFN-α (1x103 
IU/ml) or IL-27 (50 ng/ml) for 30 minutes. Lane 3 contains unlabeled hSIE probe as 
competitor; Lanes 4, 7, 10 contain a STAT1 antibody, Lanes 5, 8, 11 contain a STAT3 
antibody. Left arrows indicate STAT1 and STAT3 complexes binding to the probe: 1, 
STAT3/3 homodimers; 2, STAT3/STAT1 heterodimers; 3, STAT1/1 homodimers. Red 
arrows indicate the supershift with STAT3 antibody. 
 
3.3.4 GOF-STAT1 mutations lead to increased STAT1 transcriptional activity 
I next examined the effects of GOF-STAT1 mutations on STAT1-induced gene 
transcription. The expression of IFN-α- or IL-27-induced genes CXCL10 and IRF1 in 
mutant cells was markedly enhanced compared with control subjects. Conversely, in 
line with the comparable levels of STAT1 phosphorylation shown by WB (Fig 3.1), 
IL-21-induced STAT1-dependent gene expression was not different compared to healthy 
controls (Figure 3.9). 
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Figure 3.9 GOF-STAT1 mutations increase transcription of STAT1-dependent 
gene.  
Expression of CXCL10 and IRF1 genes in PBMCs (A) or EBV transformed cells (B) 
was assessed in AD-CMC patients (CMC) or healthy controls (HC) by qRT-PCR. Cells 
were stimulated with IFN-α (1x103 IU/ml), IL-27, IL-21 (50 ng/ml) or unstimulated (US) 
for 4 hours. Two independent experiments were performed.  
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3.4 Summary 
In the present chapter, I confirmed GOF-STAT1 mutations in AD-CMC patients led to 
increased STAT1 phosphorylation, DNA-binding activity to hSIE probe and STAT1 
target gene (CXCL10 and IRF1) induction. These mutations affected cellular response 
to cytokines including IFN-α, IFN-γ and IL-27.  
To understand the underlying mechanisms involved in the gain of STAT1 observed in 
CMC patients, I used pervanadate and staurosporine to interrogate STAT1 
dephosphorylation and phosphorylation. My results demonstrated that the impaired 
dephosphorylation of IFN-α activated mutant STAT1 could be mimicked in healthy 
controls by adding pervanadate - a phosphatase inhibitor. On the other hand, the delayed 
dephosphorylation could be normalized by blocking the initial phosphorylation with 
staurosporine - a tyrosine kinase inhibitor. Furthermore, I showed that suboptimal 
stimulation of STAT1 combined with limiting initial phosphorylation resulted in lower 
levels of STAT1 phosphorylation that allowed dephosphorylation kinetics to return to 
normal. There results indicated that the underlying mechanism involves a gain of 
STAT1 activation due to the delayed dephosphorylation as well as the enhanced initial 
phosphorylation of STAT1. 
I have demonstrated that GOF-STAT1 mutations lead to hyper-activation of STAT1 with 
enhanced and prolonged responses to STAT1-dependent cytokines. However, how this 
mutation interferes with Th-17 immunity leading to fungal infection remains unclear. 
Recent studies strongly implicated that STAT3 activation triggers transcription of IL-17 
which is crucial for mounting protective immune responses against fungi. The following 
chapter investigates how GOF-STAT1 mutations interfere with STAT3 activation and 
function. 
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CHAPTER 4 GOF-STAT1 MUTATIONS DECREASE STAT3 GENE 
TRANSCRIPTION 
 
4.1 Rationale 
The importance of Th-17 cytokines for fungal immunity in humans was only recently 
reported [96], when the critical role of STAT3 signaling for production of Th-17 
cytokines [45, 60] was identified in PID patients with the HIES, who have CMC as part 
of their clinical phenotype. Subsequent reports of additional mutations (CARD9, 
Dectin-1, TYK2, IL-17F, IL-17RA, IL-12Rβ1, ACT1 and AIRE) in PID patients with 
CMC mapped out the fungal immunity pathway [97], confirming the importance of the 
STAT3/Th-17 cytokine axis. However, the GOF-STAT1 mutations were not themselves 
on the Th-17 signaling immune pathway according to currently understanding. This 
raises the question of how GOF-STAT1 mutations interfere with STAT3 signaling and 
consequently reduce Th-17 related cytokine production.  
STAT1 and STAT3 are thought to play opposite roles in most cell types, although the 
underlying mechanisms are still not fully understood. STAT1 enhances inflammation 
and innate and adaptive immunity, triggering anti-proliferation and pro-apoptotic 
responses, while STAT3 promotes cell survival/proliferation, motility and immune 
tolerance. There is an intriguing convergence of distinct cytokine and growth factor 
receptor signaling on overlapping sets of STATs, particularly on STAT1 and STAT3 [98]. 
STAT1 is a central mediator of all types IFNs (I, II & III) by binding to GAS or ISRE 
that regulates expression of genes involved in cell cycle arrest and apoptosis [99], as 
well as IL-27 (a member of the IL-12 family) to induce STAT1-dependent inflammatory 
target gene expression [100]. STAT3 is mainly activated by IL-6, IL-23 and IL-21 and is 
essential for differentiation of Th-17 cells, recently shown to be crucial for protection 
against fungal infections, whilst mediating cell proliferation and survival. However, 
type II IFNs can in addition activate STAT3 [85, 101]. Activated STAT1 and STAT3 can 
bind to the same DNA sequences as either homodimers or STAT1/3 heterodimers [102], 
but trigger the transcription of a different set of genes [103].  
The regulation of STAT activity is dependent on initial phosphorylation in the 
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cytoplasm, translocation to the nucleus, subsequent DNA binding at cytokine-inducible 
promoter regions and activation of gene transcription. To investigate how enhanced 
STAT1 activation interferes with STAT3-dependent IL-17 production, in this chapter, I 
present results investigating STAT3 phosphorylation, nuclear translocation, 
DNA-binding and gene transcription in CMC patients harbouring GOF-STAT1 
mutations. 
 
4.2 Aims 
In the presence of GOF-STAT1 mutations: 
 Investigate the effect on STAT3 activation/phosphorylation 
 Assess nuclear translocation of phosphorylated STAT3 
 Evaluate the effect on STAT3 DNA-binding activity 
 Determine downstream effect on STAT3-dependent gene induction 
 
4.3 Results 
4.3.1 STAT3 phosphorylation in the presence of GOF-STAT1 mutations is not reduced 
To evaluate STAT3 activation, I stimulated PBMCs with IL-23 as an improtant cytokine 
for Th-17 cells proliferation and expansion. Optimization of IL-23-induced STAT3 
phosphorylation was shown in Fig 4.1, where phytohemagglutinin (PHA) was used as a 
mitogen to trigger T cell division, whilst IL-2 was used to activate T cell proliferation 
and differentiation. I found that in normal PBMCs, IL-23-induced STAT3 
phosphorylation could be detected in the presence of PHA and IL-2 for 3 days before 
exposing to IL-23 stimulation. Follow this culture condition, the results showed that 
IL-23-induced STAT3 phosphorylation/activation in the presence of GOF-STAT1 
mutations was not reduced (Fig 4.2A). In addition, I compared STAT3 phosphorylation 
in CMC patients to healthy controls upon stimulation with other 
STAT1/STAT3-activating cytokines (IL-6, IFN-α, IL-21 and IL-27) in both PBMCs and 
EBV transformed cells. Consistent with IL-23 stimulation data, STAT3 phosphorylation 
in GOF-STAT1 mutations was not reduced as was expected, but was similar or even 
increased compared to control EBV cells (Fig 4.2B and C). 
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Figure 4.1 Optimization of IL-23-induced STAT3 phosphorylation. 
A. Western blotting was performed on nuclear extracts from IL-23-stimulated PBMCs 
with indicated doses and time periods. B. WB of whole cell lysates from CD4
+
T cells 
pre-cultured with PHA (2 μg/ml) and IL-2 (40 IU/ml) for 3 days with or without 
addition of IL-23 (10 ng/ml), followed by IL-23 (100 ng/ml) stimulation for 30 minutes. 
C. Optimization of cell number for whole cell lysates extraction by comparing 
IL-23-induced STAT3 phosphorylation in CD4
+
T cells and PBMCs with PHA and IL-2 
pre-treatment. D. Kinetics of IL-23-induced STAT3 phosphorylation was studied by WB 
on whole cell lysates extracted from PBMCs (3x10
6
) with PHA and IL-2 pre-treatment. 
Anti-GAPDH and anti-Histone H3 antibodies were used as cytoplasmic and nuclear 
markers, respectively. 
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Figure 4.2 STAT3 phosphorylation in the presence of GOF-STAT1 mutations is not 
reduced.  
Western blotting was performed on whole cell lysates from healthy controls (HC) and 
CMC patients (CMC) with GOF-STAT1 mutations. (A) IL-23-induced STAT3 
phosphorylation in PBMCs. Cells were pre-cultured with PHA (2 μg/ml) and IL-2 (40 
IU/ml) for 3 days and stimulated with IL-23 (100 ng/ml) for 30 minutes before lysing. 
Various cytokines induced STAT3 phosphorylation in PBMCs (B) or EBV transformed 
cells (C). Prior to lysing, cells were stimulated for 15 minutes with 50 ng/ml IL-6, IL-21, 
30 minutes with 1x10
3
 IU/ml IFN-γ, IFN-α or 50 ng/ml IL-27. Data shown are 
representative of at least 3 independent experiments. 
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4.3.2 Phosphorylated STAT3 translocates to the nucleus in cells with GOF-STAT1 
mutations 
I next hypothesized that the decreased IL-17 production in CMC patients with 
GOF-STAT1 mutations could be due to impaired STAT3 nuclear translocation. To 
evaluate this possibility, I prepared nuclear, cytoplasmic and total cell extracts from 
IL-23-stimulated PBMCs or IFN-α-stimulated EBV cell lines and checked for the 
presence of phosphorylated STAT3. As shown in Fig 4.3, both IL-23 and IFN-α 
stimulation led to a comparable accumulation of phospho-STAT3 in the nuclei of cells 
from CMC patients and healthy controls.  
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Figure 4.3 Nuclear translocation of STAT3 upon IL-23 or IFN-α stimulation in 
cells with GOF-STAT1 mutations.  
PBMCs were pre-cultured with PHA and IL-2 and stimulated with IL-23 (A) or EBV 
cells were stimulated with IFN-α (B) as described above. Nuclear, cytoplasmic and total 
cell extracts were prepared from same number of cells. Extracts were then blotted and 
membranes were probed with anti-phospho-STAT3 (Tyr705) and anti-STAT3 antibodies. 
Anti-GAPDH and anti-Lamin A/C antibodies were used as cytoplasmic and nuclear 
markers, respectively. Results are representative of 2 independent experiments. 
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4.3.3 STAT3 DNA-binding is maintained in cells with GOF- STAT1 mutations 
To investigate whether low STAT3-dependent IL-17 production in patients with 
GOF-STAT1 mutations was due to impaired STAT3 DNA-binding, I assessed STAT3 
binding to a STAT-consensus binding site element (hSIE) in EMSA as well as in an 
ELISA-based hSIE-binding kit (TransAM STAT3 Kit). My EMSA results showed that 
IL-21-induced STAT3 homodimers binding to hSIE probe was comparable in cells from 
CMC patients to those from healthy controls, whilst IFN-α- and IL-27-induced STAT1/3 
heterodimers DNA-binding to hSIE was mildly increased in cells from CMC patients to 
those from healthy controls (Fig 4.4). Additionally, similar levels of STAT3 binding in 
CMC patients and controls were observed in the TransAM hSIE-binding assay (Fig 
4.5).  
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Figure 4.4 Comparable levels of STAT3 binding to the hSIE probe in STAT1 
mutant cells and controls evaluated in EMSA. 
DNA binding was assessed using the hSIE probe and nuclear extracts from EBV 
transformed cells derived from healthy controls (HC) and CMC patients (CMC) 
following stimulation with IL-6, IL-21 (50 ng/ml) for 15 minutes, or IFN-α, IFN-γ 
(1x10
3
 IU/ml), IL-27 (50 ng/ml) for 30 minutes. Arrows indicate STAT1 and STAT3 
complexes binding to the probe: 1, STAT3/3 homodimers; 2, STAT1/STAT3 
heterodimers; 3, STAT1/1 homodimers. Results are representative of at least 3 
independent experiments. 
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Figure 4.5 Comparable levels of STAT3 binding to the hSIE in STAT1 mutant cells 
and controls evaluated in the TransAM ELISA-based assay.  
Nuclear extracts from unstimulated (US) and IL-23-stimulated PBMCs (A) or IFN-α-, 
IL-27- and IL-21-stimulated EBV cells derived from healthy controls (HC) and CMC 
patients (CMC) were incubated with immobilized hSIE and bound STAT3 was detected 
using a STAT3 antibody according to the TransAM Kit instructions. Nuclear extracts of 
IL-6-stimulated Hep G2 cells (supplied in the TransAM kit) were used as a positive 
control. Results are representative of 2 independent experiments. 
 
To further confirm STAT3 DNA-binding in GOF-STAT1 mutations was maintained, I 
investigated the occupancy of STAT3 at the c-Fos promoter by ChIP assay. Results 
showed that IFN-α stimulation induced the recruitment and binding of STAT3 at its 
endogenous c-Fos promoter in a CMC patient was decreased compared to a control (Fig 
4.6).  
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Figure 4.6 Occupancy at the c-Fos promoter by STAT3 is maintained in the 
presence of GOF-STAT1 mutations.  
ChIP assay was carried out using 25 μg cross-linked chromatin prepared from IFN-α 
(1x10
3
 IU/ml, 30 minutes) stimulated EBV transformed cell lines derived from a 
healthy control and a CMC patient with GOF-STAT1. Antibodies used for 
immunoprecipitation were both rabbit polyclonal raised against STAT3 or a control 
antibody Immunoglobulin G (IgG). Three micrograms of STAT3 antibody or IgG were 
used in each ChIP reaction. Immunoprecipitated DNA was subjected to qRT-PCR using 
c-Fos primers. Each PCR reaction was performed in triplicate. A signal intensity value 
for each sample was calculated from the average of the experiments. Average values of 
eluates were normalized to average values of control antibody sample and expressed as 
fold enrichment above background (i.e. IgG).  
 
4.3.4 GOF- STAT1mutations lead to decreased STAT3 transcriptional activity 
The above results suggested the disruption of STAT3-dependent IL-17 production in the 
presence of GOF-STAT1 mutations may occur at the level of gene transcription. To 
address this, the following experiments aimed to investigate whether GOF-STAT1 
mutations have an effect on transcription of STAT3-induced genes. I stimulated PBMCs 
with IL-23 and measured transcription of the Th-17 related transcription factors: RORc, 
IL-17A and IL-22 as well as a non-Th-17 related but STAT3-dependent gene IL-10. The 
results demonstrated that GOF-STAT1 mutations decreased the transcription of both 
Th-17 and non-Th-17 related but STAT3-induced genes (Fig 4.7). In addition, I 
investigated other STAT3-induced gene transcription following stimulation with various 
STAT1/STAT3-activating cytokines in both PBMCs and EBV cell lines. Consistently, 
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results showed that all these STAT3-dependent genes (c-Fos, SOCS3, c-Myc) were 
down-regulated in cells with GOF-mutations of STAT1 (Figs 4.8 and 4.9). This broad 
effect of GOF-STAT1 on decreasing STAT3-dependent gene transcription might explain 
the reduced IL-17 levels in CMC patients with STAT1 mutations. 
 
0
5
10
15
20
US
HC
CMC
IL-23
**
IL
-1
7
A
 m
R
N
A
 (
fo
ld
 i
n
c
re
a
s
e
)
0
5
10
15
20
US
HC
CMC
IL-23
**
R
O
R
c
 m
R
N
A
 (
fo
ld
 i
n
c
re
a
s
e
)
0
5
10
15
20 HC
CMC
US IL-23
**
IL
-1
0
 m
R
N
A
 (
fo
ld
 i
n
c
re
a
s
e
)
IL-23
RORc
IL-17A
IL-22
IL-10
Cytokine Treatment
G
e
n
e
 E
x
p
re
s
s
io
n
G
e
n
e
 E
x
p
re
s
s
io
n
IL-23
0
5
10
15
20
US
HC
CMC
IL-23
**
IL
-2
2
 m
R
N
A
 (
fo
ld
 i
n
c
re
a
s
e
)
 
 
Figure 4.7 Decreased transcription of STAT3-induced genes in the presence of 
GOF-STAT1 mutations in IL-23-stimulated PBMCs.  
Expression of RORc, IL-17A, IL-22 and IL-10 genes in PBMCs was assessed in CMC 
patients with GOF-STAT1 mutations (CMC) and healthy controls (HC) by qRT-PCR 
(Mean±SEM). PBMCs were pre-cultured with PHA (2 μg/ml) and IL-2 (40 IU/ml) for 
3 days and then stimulated with IL-23 (100 ng/ml) or were left unstimulated (US) for 4 
hours (** P ≤ 0.01). 
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Figure 4.8 Decreased transcription of STAT3-induced genes in the presence of 
GOF-STAT1 mutations in PBMCs stimulated with IFN-α, IL-27 or IL-21.  
Expression of c-Fos, SOCS3 and c-Myc genes in PBMCs was assessed in CMC patients 
with GOF-STAT1 mutations (CMC) and healthy controls (HC) by qRT-PCR. Cells were 
stimulated with IFN-α (1x103 IU/ml), IL-27 and IL-21 (50 ng/ml) or left unstimulated 
(US) for 4 hours. 
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Figure 4.9 Decreased transcription of STAT3-dependent genes in presence of 
GOF-STAT1 mutations in EBV transformed cells stimulated with IFN-α, IL-27 or 
IL-21.  
Expression of c-Fos, SOCS3 and c-Myc genes in EBV transformed cells was assessed 
in CMC patients with GOF-STAT1 mutations (CMC) or healthy controls (HC) by 
qRT-PCR (Mean±SEM). Cells were stimulated with IFN-α (1x103 IU/ml), IL-27 and 
IL-21 (50 ng/ml) or left unstimulated (US) for 4 hours (** P ≤ 0.01, ns=not significant). 
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To evaluate the transcriptional activity of STAT3 in cells with GOF-mutations of STAT1, 
I intended to perform STAT3 Luciferase Assay (Cignal Report Assay, Qiagen) in EBV 
transformed cells from both CMC patients and healthy controls. STAT3 reporter assays 
can provide a quantitative assessment of STAT3 signal transduction activation by 
measuring the activities of downstream transcription factors. However, this reporter 
assay is established on a stable and successful cell transfection, which could be assessed 
by monitoring GFP expression (supplied in the assay as a positive control). My results 
revealed that the transfection efficiency of EBV cells was very low, as it is well known 
that primary human cells are difficult to transfect. Conversely, the transfection 
efficiency of an adherent human chondrocyte cell line (SW cells) was far better (Fig 
4.10). These results suggested that EBV cell lines are difficult to transfect and not 
suitable for performing STAT3 Reporter Assays. 
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Figure 4.10 Comparison of cell transfection efficiency in EBV cells and SW cells. 
Cell transfection was carried out in SW cells (A) and EBV transformed cells (B) with 
GFP tagged positive control for 48 hours transfection. The amount of DNA and 
Attractene Reagent is given in Table 2.2. GFP positive control was used from the Cignal 
Report Assay kit (40:1:1 mixture of constitutively expressing GPF, firefly luciferase and 
Renilla luciferase constructs).  
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4.4 Summary 
It has been suggested that STAT1 and STAT3 oppose each other in many biological 
processes [104]. In the present chapter, I investigated how enhanced STAT1 activation 
interferes with STAT3 activation and signaling in CMC patients. My results showed that 
STAT3 phosphorylation in the presence of GOF-STAT1 mutations was not reduced 
following stimulation of PBMCs with a selective STAT3-activating cytokine (IL-23) 
and STAT1/STAT3-activating cytokines (IFN-α, IL-21 and IL-27). The unimpaired 
phosphorylation of STAT3 was also confirmed in EBV transformed cells with 
GOF-STAT1 mutations following stimulation with IFN-α, IL-21 and IL-27. Both IL-23 
and IFN-α induced phosphorylated STAT3 could translocate into nuclei of cells with 
GOF-mutations of STAT1. Cytokine (IL-23, IFN-α, IL-21 and IL-27) activated STAT3 
binding to hSIE was maintained in cells bearing GOF-STAT1 mutations. However, the 
recruitment of activated STAT3 to its endogenous target gene promoter (c-Fos) was 
decreased in EBV cells with GOF-mutations of STAT1. Furthermore, in contrast with 
healthy controls, the transcription of STAT3-dependent genes induced by cytokine 
(IL-23, IFN-α, IL-27 and IL-21) stimulation was markedly reduced. Impaired 
STAT3-inducible gene transcription included both Th-17 (RORc, IL-17, IL-22) and 
non-Th-17 (IL-10, c-Fos, SOCS3, c-Myc) related genes in cells with GOF-STAT1 
mutations. The broad defective transcription of STAT3-dependent gene might explain 
the reduced IL-17 levels and other clinical phenotypes in CMC patients harbouring 
GOF-STAT1 mutations.  
I have demonstrated the GOF-STAT1 mutations lead to decreased transcription of 
STAT3-induced gene, which might be the mechanism underlying reduced Th-17 related 
cytokine levels in CMC patients. In the following chapter I investigate whether 
inhibition of enhanced STAT1 signaling improves STAT3 function in these CMC 
patients. 
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CHAPTER 5 INHIBITION OF STAT1 ENHANCES STAT3 GENE 
TRANSCRIPTION IN CMC 
 
5.1 Rationale 
Fludarabine is a chemotherapy drug known as an antimetabolite. It is used in the 
treatment of hematological malignancies (cancers of blood cells such as leukemias and 
lymphomas). Fludarabine can prevent cells from making DNA and RNA, which stops 
cell growth and causes cell death. It has been shown that fludarabine can also induce 
significant reduction of STAT1 phosphorylation without affecting other STAT proteins 
[105, 106]. It is therefore recognized as a STAT1 activation inhibitor. 
STAT1 mutations identified in AD-CMC patients are gain-of-function. In the previous 
chapter I have shown that the enhanced STAT1 activation interferes with STAT3 
signaling at the gene transcription level, where GOF-STAT1 decreases STAT3-induced 
transcription of both Th-17 and non-Th-17 related genes. This is likely the underlying 
mechanism of low IL-17 production in CMC patients with these mutations. In this 
chapter, I present results demonstrating how inhibition by fludarabine of the STAT1 
hyper-phosphorylation/activation caused by the GOF-STAT1 mutations in CMC 
patients influences STAT3-induced gene transcription and IL-17 production. 
 
5.2 Aims 
In the presence of fludarabine in GOF-STAT1 mutant cells: 
 Investigate STAT1 and STAT3 phosphorylation 
 Evaluate the effect on STAT1- and STAT3-induced gene transcription 
 Assess the effect on Candida albicans-induced cytokine production 
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5.3 Results 
5.3.1 Fludarabine inhibits STAT1 phosphorylation without affecting phosphorylation 
of STAT3 
To evaluate the effect of fludarabine on cytokine-induced STAT1 and STAT3 activation, 
I assessed EBV transformed cells from a healthy donor and either left them untreated or 
exposed them to fludarabine, then stimulated them with IL-21 (a cytokine which 
strongly activates both STAT1 and STAT3 signaling in EBV cells). Results showed that 
fludarabine led to a dose-dependent inhibition of STAT1 activation after IL-21 treatment 
of EBV cells (Fig 5.1). In contrast, phosphorylation of STAT3 induced by IL-21 was 
only minimally affected by fludarabine treatment (Fig 5.1). Thus, fludarabine induced a 
specific defect in STAT1 activation following cytokine stimulation. No effect of 
fludarabine on cell viability was confirmed by cell proliferation assay (Promega) (Fig 
5.2). 
 
STAT1
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- - 5      10     50     100Fludarabine
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Figure 5.1 Fludarabine inhibits STAT1 phosphorylation without affecting 
phosphorylation of STAT3.  
Western blotting was performed on whole cell lysates of EBV transformed cells derived 
from a healthy subject. Prior to lysing, cells were left untreated or exposed to 
fludarabine at the indicated doses for 1 hour, then stimulated with IL-21 (50 ng/ml) for 
15 minutes.  
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Figure 5.2 Effect of fludarabine doses on cell viability in short time culture.  
After four hours in the presence of fludarabine (at the indicated doses), cell viability 
was assessed by measuring the activity of mitochondrial reductase enzymes on 
formazan production. Mean optical density from triplicate wells of treated cells was 
compared to untreated cells (expressed as 100%). 
 
5.3.2 Fludarabine improves STAT3-induced gene transcription in cells with 
GOF-STAT1 mutations  
Given that fludarabine induced specific inhibition of STAT1 phosphorylation, I next 
assessed its effect on downstream STAT1- and STAT3-induced gene transcription. 
Results showed that fludarabine led to substantial inhibition of IFN-α- and 
IL-27-induced STAT1-dependnet gene (CXCL10 and IRF1) transcription in EBV cells 
from both healthy controls and CMC patients (Fig 5.3). Interestingly, transient 
inhibition of STAT1 activation improved transcription of IL-23-activated Th-17 related 
genes (RORc, IL-17A and IL-22) in cells from CMC patients, which approached levels 
seen in healthy controls (Fig 5.4). This improved STAT3-dependent gene transcription 
was also observed in IFN-α-, IL-27- and IL-21-induced c-Fos and SOCS3 gene 
expression in EBV cell lines from CMC patients with GOF-STAT1 mutations (Fig 5.5). 
However, no obvious difference was seen for IL-10 and c-Myc gene transcription (Fig 
5.5). 
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Figure 5.3 Fludarabine reduces previously high GOF-STAT1-dependent gene 
transcription. 
Expression of CXCL10 and IRF1 genes in EBV transformed cells was assessed in CMC 
patients with GOF-STAT1 mutations (CMC) or healthy controls (HC) by qRT-PCR 
(Mean±SEM). Cells were stimulated with IFN-α (1x103 IU/ml) and IL-27 (50 ng/ml) 
or left unstimulated (US) for 4 hours, fludarabine (FLU) 100 μg/ml was added 1 hour 
before cytokine stimulation (* P≤ 0.05, ** P ≤ 0.01). 
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Figure 5.4 Fludarabine improves low STAT3-induced gene transcription in PBMCs 
with GOF-STAT1 mutations. 
Expression of RORc, IL-17A, IL-22 and IL-10 genes in PBMCs was assessed in CMC 
patients or healthy controls by qRT-PCR. Cells were stimulated with IL-23 (100 ng/ml) 
for 4 hours, fludarabine (FLU) 100 μg/ml was added 1 hour before cytokine stimulation. 
Relative effect of fludarabine on IL-23 stimulated STAT3-denpendent gene expression 
in CMC patients is shown as a percentage of the levels in healthy controls which are 
presented as 100% (dotted line) (Mean±SEM).  
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Figure 5.5 Fludarabine improves low STAT3-induced gene transcription in EBV 
cells with GOF-STAT1 mutations. 
Expression of c-Fos, SOCS3, c-Myc and IL-10 genes in EBV cells was assessed in 
CMC patients or healthy controls by qRT-PCR. Cells were stimulated with IFN-α 
(1x10
3 
IU/ml), IL-27 or IL-21 (50 ng/ml) for 4 hours, fludarabine (FLU) 100 μg/ml was 
added 1 hour before cytokine stimulation. Relative effect of fludarabine on 
cytokine-induced STAT3 gene expression in CMC patients is shown as a percentage of 
the levels in healthy controls which are presented as 100% (dotted line) (Mean±SEM). 
 
5.3.3 Fludarabine cannot rescue low IL-17 production in CMC patients with 
GOF-STAT1 mutations 
The above results suggested that transient inhibition of STAT1 in CMC patients with 
GOF-STAT1 mutations might improve low STAT3-indcued gene transcription. The next 
experiments aimed to investigate whether low IL-17 production could indeed be 
restored in CMC patients in the presence of fludarabine. To address this, I assessed 
PBMCs collected from CMC patients with GOF-STAT1 mutations and healthy controls 
 62 
and either left them untreated or exposed them to Candida albicans with the addition of 
fludarabine for 5 days. Cytokine production in cell culture supernatant was measured by 
ELISA. My results confirmed the previous findings of low IL-17 and IL-22 production 
in CMC patient cells exposed to Candida albicans. IL-10 production is also lower in 
CMC patients than healthy subjects. However, upon addition of fludarabine to cell 
cultures of either healthy controls or CMC patients, hardly any cytokine production was 
seen (Fig 5.6), suggesting that the presence of fludarabine in long-term cultures was 
unable to restore low IL-17 or IL-22 production in cells with GOF-STAT1 mutations. 
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Figure 5.6 Cytokine production of Candida albicans-stimulated PBMCs in the 
presence of fludarabine.  
Cytokine production of IL-17, IL-22 and IL-10 in Candida albicans-stimulated PBMCs 
was assessed in 2 CMC patients with GOF-STAT1 mutations (CMC) and 2 healthy 
controls (HC) by ELISA. Cells were left unstimulated (US) or stimulated with Candida 
albicans (1:15x10
3
 dilution) with or without fludarabine (FLU) 100 μg/ml for 5 days. 
Amphotericin B (2.5 μg/ml) was added at day 0 and day 3 to prevent Candida albicans 
overgrowth. 
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Figure 5.7 Effect of fludarabine on cell viability in lone-term culture. 
PBMCs from healthy control were left unstimulated (US) or stimulated with Candida 
albicans (1:15x10
3
 dilution) with or without fludarabine (FLU) 100 μg/ml for 5 days. 
Amphotericin B (2.5 μg/ml) was added at day 0 and day 3 to prevent Candida albicans 
overgrowth. Cell viability was assessed on day 5 by measuring the activity of 
mitochondrial reductase enzymes on formazan production. Mean optical density from 
triplicate wells of treated cells was compared to untreated cells (expressed as 100%). 
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5.4 Summary 
The low STAT3-induced gene transcription caused by STAT1 hyper-activation in CMC 
patients bearing GOF-STAT1 mutations may be the cause of low IL-17 production seen 
in these patients and their consequent susceptibility to Candida infections. In the present 
chapter, I used a STAT1 inhibitor (fludarabine) to inhibit STAT1 activation and 
investigated its effects on STAT3 phosphorylation and transcription. I confirmed the 
specificity of fludarabine for inhibition of STAT1 activation and by demonstrating a 
dose-dependent inhibition of STAT1 phosphorylation without affecting STAT3. In line 
with this, fludarabine significantly inhibited downstream STAT1-dependent gene 
(CXCL10 and IRF1) transcription in both healthy controls and CMC patients. Moreover, 
fludarabine treatment improved low transcription of Th-17 related genes (RORc, 
IL-17A and IL-22) expression in IL-23-stimulated PBMCs and other STAT3-dependent 
gene (c-Fos and SOCS3) in IFN-α-, IL-27- and IL-21-stimulated EBV cells from CMC 
patients with GOF-STAT1 mutations. Although transient inhibition of STAT1 improved 
STAT3-dependent gene transcription, long-term exposure to fludarabine in Candida 
albicans-stimulated PBMCs cultures could not restore low IL-17 and IL-22 production 
in CMC patients, due to the long-term culture with a high dose (100 μg/ml) of 
fludarabine could cause cell death.  
The above results demonstrate that fludarabine treatment can transiently improve low 
STAT3-induced gene transcription in CMC patients but still cannot restore low Th-17 
cytokine production. As recent data strongly implicate epigenetic regulation of gene 
transcription by acetylation, in the following chapter I investigate whether the disrupted 
STAT3 function in CMC patients with GOF-STAT1 mutations could be modified by 
regulating acetylation. 
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CHAPTER 6 MODIFICATION OF ACETYLATION ALTERS 
STAT3 FUNCTION 
 
6.1 Rationale 
Unlike phosphorylation/dephosphorylation, which mainly acts as an on/off switch for 
STAT activity, post-translational covalent modification of histones like acetylation and 
methylation have recently been shown to critically modify STAT-dependent intracellular 
signaling [84]. The extent of histone acetylation is determined by the activities of the 
enzymes, HDACs and HATs [107]. Various chemically and structurally diverse agents 
have been discovered which specifically inhibit HDAC activity. These include the 
natural product trichostatin A (TSA) which has a broad spectrum of epigenetic activities 
and has been investigated as a potential anti-cancer drug [108]. 
The enhanced STAT1 activation and function caused by GOF-mutations identified in 
CMC decreases STAT3-induced transcription of both Th-17 and non-Th-17 related 
genes. Although inhibition of STAT1 by fludarabine can transiently improve low 
STAT3-induced gene transcription, it cannot restore low Th-17 cytokine production in 
CMC patients as demonstrated in the previous chapter. In this chapter, I investigated 
whether the disrupted STAT3 function in CMC patients with GOF-STAT1 mutations 
could be modified by regulating acetylation.  
 
6.2 Aims 
In the presence of GOF-STAT1 mutations: 
 Investigate the effect of TSA on STAT1 and STAT3 phosphorylation 
 Evaluate the effect of TSA on STAT1- and STAT3-induced gene transcription 
 Assess the effect of TSA on Candida albicans-induced cytokine production 
 Identify which HDACs are involved in regulating STAT3-induced gene 
transcription 
 Investigate the combined effect of TSA and fludarabine on STAT3-induced gene 
transcription 
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6.3 Results 
6.3.1 TSA does not alter phosphorylation of STAT1 and STAT3 
To evaluate the effect of TSA on cytokine-induced STAT1 and STAT3 activation, I 
assessed phosphorylation of STAT1 and STAT3 following stimulation of PBMCs with 
IL-23 or EBV transformed cells with IFN-α from healthy controls and AD-CMC 
patients. To avoid cell toxicity, the dose-dependent effect of TSA on cell viability was 
assessed by cell proliferation assay (Promega). Fig 6.1 showed that there was no 
significant toxicity at 100 ng/ml of TSA. With the same dose, TSA did not alter IL-23 
and IFN-α-induced phosphorylation of STAT1 and STAT3 in either healthy controls or 
CMC patients (Fig 6.2).  
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Figure 6.1 Effect of TSA doses on cell viability.  
After four hours addition of TSA at the indicated doses, cell viability was assessed by 
measuring the activity of mitochondrial reductase enzymes on formazan production. 
Mean optical density from triplicate wells of treated cells was compared to untreated 
cells (expressed as 100%). 
 
 67 
GAPDH
STAT3
pSTAT3
TSA
(100ng/ml)
IL-23
(100ng/ml) - +        +        - +        +
- - +        - - +
HC CMCa37
GAPDH
STAT3
pSTAT3
STAT1
pSTAT1
- +        +        - +        +
- - +        - - +
IFNα
(1x103IU/ml)
TSA
(100ng/ml)
HC CMCa38
90 KDa
90 KDa
37 KDa
90 KDa
90 KDa
90 KDa
90 KDa
37 KDa
A
B
 
 
Figure 6.2 TSA does not alter cytokine-induced phosphorylation of STAT1 and 
STAT3.  
Western blotting was performed on whole cell lysates of PBMCs (A) or EBV 
transformed cells (B) derived from healthy controls (HC) and CMC patients with 
GOF-STAT1 mutations (CMC). Prior to lysing, cells were left untreated or exposed to 
TSA (100 ng/ml) together with IL-23 (100 ng/ml) for 30 minutes in PBMC cultures 
(pre-cultured with 2 μg/ml PHA and 40 IU/ml IL-2 for 3 days) or IFN-α (1x103 IU/ml) 
for 15 minutes in cultures of EBV cell lines. GAPDH was used as a loading control. 
 
6.3.2 TSA accelerates prolonged dephosphorylation of STAT1 in cells with 
GOF-STAT1 mutations 
GOF-STAT1 mutations led to a delayed dephosphorylation of STAT1 for up to 90 
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minutes in CMC patients as previously demonstrated. However, addition of TSA 
allowed dephosphorylation to take place with similar kinetics as in normal cells (Fig 
6.3). 
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Figure 6.3 TSA accelerates delayed dephosphorylation of STAT1 in cells with 
GOF-STAT1 mutations. 
Dephosphorylation in EBV transformed cells from a CMC patient (CMC) and a healthy 
control (HC) stimulated with IFN-α (1x103 IU/ml) with or without TSA (100 ng/ml) for 
the indicated time periods. GAPDH was used as a loading control. 
 
6.3.3 TSA alters STAT1- and STAT3-induced gene transcription in cells with 
GOF-STAT1 mutations 
I next assessed the effect of TSA on downstream STAT1- and STAT3-induced gene 
transcription. My results showed that TSA reduced IFN-α, IL-27 and IL-21-induced 
transcription of STAT1-dependnet genes (CXCL10 and IRF1) in EBV cell lines from 
CMC patients to levels that were lower than in healthy controls (Fig 6.4). Conversely, in 
PBMCs from CMC patients, addition of TSA increased low transcription levels of 
IL-23-activated Th-17 dependent genes (IL-17, IL-22 and marginally RORc) to levels 
seen in healthy controls (Fig 6.5 A). This was however, not the case for IL-10 gene 
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transcription (Fig 6.5A). The increased STAT3-dependent gene transcription was also 
observed in IFN-α-, IL-27- and IL-21-induced c-Fos and SOCS3 gene expression in 
EBV cells with GOF-STAT1 mutations (Fig 6.5B). However, no obvious difference was 
seen for IL-10 and c-Myc gene expression (Fig 6.5B). 
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Figure 6.4 TSA decreases STAT1-induced gene transcription in EBV cells with 
GOF-STAT1 mutations. 
Expression of CXCL10 and IRF1 genes in EBV transformed cells was assessed in CMC 
patients with GOF-STAT1 mutations or healthy controls by qRT-PCR. Cells were 
stimulated with IFN-α (1x103 IU/ml), IL-27 or IL-21 (50 ng/ml) with or without TSA 
(100 ng/ml) for 4 hours. Relative effect of TSA on cytokine-induced STAT1 gene 
expression in CMC patients is shown as percentage of levels in healthy controls which 
are presented as 100% (dotted line) (Mean±SEM).  
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Figure 6.5 TSA increases low STAT3-induced gene transcription in cells with 
GOF-STAT1 mutations. 
Expression of RORc, IL-17, IL-22 and IL-10 genes in PBMCs (A), or c-Fos, SOCS3, 
c-Myc and IL-10 genes in EBV transformed cells (B) was assessed in CMC patients 
with GOF-STAT1 mutations or healthy controls by qRT-PCR. Cells were stimulated 
with IL-23 (100 ng/ml, with PHA and IL-2 pre-treatment), IFN-α (1x103 IU/ml), IL-27 
and IL-21 (50 ng/ml) with or without TSA (100 ng/ml) for 4 hours. Relative effect of 
TSA on cytokine-induced STAT3 gene expression in CMC patients is shown as 
percentage of levels in healthy controls which are presented as 100% (dotted line) 
(Mean±SEM). 
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6.3.4 TSA increases Candida albicans-induced IL-22 production in cells with 
GOF-STAT1 mutations 
Given that addition of TSA which promotes acetylation in cells with GOF-STAT1 
mutations increased low STAT3-induced gene transcription, the next experiments aimed 
to investigate whether low Th-17 related cytokine production could be restored in CMC 
patients in the presence of TSA. My results confirmed that Candida albicans-induced 
IL-17 and IL-22 production from CMC patients’ cells was barely detectable. Production 
of IL-17 increased in healthy subjects with addition of TSA but not in CMC patients. 
Interestingly, production of IL-22 increased in both healthy controls and CMC patients 
with addition of TSA. In contrast, IL-10 which was produced at comparable levels in 
healthy controls and CMC patients was reduced upon addition of TSA (Fig 6.6). These 
findings demonstrated that TSA which promotes acetylation can increase low IL-22 
production in cells from CMC patients with GOF-STAT1 mutations. 
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Figure 6.6 Cytokine production of Candida albicans-stimulated PBMCs in presence 
of TSA.  
Cytokine production of IL-17, IL-22 and IL-10 in Candida albicans-stimulated PBMCs 
was assessed in 2 CMC patients with GOF-STAT1 mutations (CMC) and 2 healthy 
controls (HC) by ELISA. Cells were left unstimulated (US) or stimulated with Candida 
albicans (1:15x10
3
 dilution) with or without TSA (100 ng/ml) for 5 days. Amphotericin 
B (2.5 μg/ml) was added at day 0 and day 3 to prevent Candida albicans overgrowth. 
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6.3.5 HDAC1 may be involved in regulating STAT3-induced gene transcription in cells 
with GOF-STAT1 mutations 
Given that TSA, a non-selective HDAC inhibitor, could increase low STAT3-induced 
gene transcription in cells with GOF-STAT1 mutations, subsequent experiments were 
carried out to identify which HDACs are involved in modulating STAT3 gene induction. 
I therefore transfected cells with siRNA targeting HDAC1, HDAC2 and HDAC3 
individually or with an irrelevant siRNA (as a negative control) and assessed 
cytokine-induced STAT3-dependent gene expression. Results showed that silencing 
HDAC1 increased IL-23-induced RORc, IL-17A and IL-22 gene expression in PBMCs 
from a healthy control but did not have much effect in CMC patient cells. Silencing 
HDAC2 had a marginal effect on STAT3-dependent gene expression in patient cells, 
whilst silencing HDAC3 appeared to have no effect at all (Fig 6.7A). Silencing HDAC1 
in EBV transformed cells from two CMC patients’ enhanced IFN-α-induced c-Fos and 
SOCS3 genes transcription (Fig 6.8A). Gene silencing efficiency was confirmed by 
immunoblotting of total lysates with specific antibodies against HDAC1, HDAC2 and 
HDAC3 (Figs 6.7B and Fig 6.8B). These results indicate that HDAC1 but not HDAC2 
or HDAC3 is likely to be involved in regulating STAT3-induced gene transcription. 
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Figure 6.7 HDAC1 but not HDAC2 or HDAC3 regulates STAT3-induced gene 
transcription in normal PBMCs.  
A. Expression of RORc, IL-17A and IL-22 genes was assessed in PBMCs from a CMC 
patient with GOF-STAT1 mutation and a healthy control by qRT-PCR. Cells were 
transfected with 1 μM solution of Accell SMARTpool siRNA targeting the HDAC1, 
HDAC2, HDAC3, and a non-targeting siRNA (NT, negative control) for 72 hours in the 
presence of PHA (2 μg/ml) and IL-2 (40 IU/ml). After transfection, cells were left 
unstimulated (US) or stimulated with IL-23 (100 ng/ml) for 4 hours. B. Gene silencing 
efficiency was assessed by blotting the total cell extracts with anti-HDAC1, 
anti-HDAC2, anti-HDAC3, and anti-GAPDH antibodies at 96 hours after transfection. 
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Figure 6.8 HDAC1 but not HDAC2 regulates STAT3-induced gene transcription in 
EBV cells with GOF-STAT1 mutations.  
A. Expression of c-Fos and SOCS3 genes was assessed in EBV transformed cells 
derived from 2 CMC patients with GOF-STAT1 mutations by qRT-PCR. Cells were 
transfected with 1 μM solution of Accell SMARTpool siRNA targeting the HDAC1, 
HDAC2, and a non-targeting siRNA (NT, negative control) for 72 hours. After 
transfection, cells were left unstimulated (US) or stimulated with IFN-α (1x103 IU/ml) 
for 4 hours. B. Gene silencing efficiency was assessed by blotting the total cell extracts 
with anti-HDAC1, anti-HDAC2, and anti-GAPDH antibodies at 96 hours after 
transfection. 
 
6.3.6 TSA and fludarabine have a synergistic effect on STAT3-induced gene 
transcription in cells with GOF-mutations of STAT1 
Although restored acetylation can increase low STAT3-induced gene transcription and 
low IL-22 production, TSA cannot fully restore disrupted STAT3 function in cells with 
GOF-STAT1 mutations, similar to that observed with fludarabine treatment (chapter 5). 
I therefore further investigated the combined effect of TSA and fludarabine on 
STAT3-induced gene transcription in CMC patients. Previous experiments demonstrated 
significant differences between IL-23-induced STAT3-dependent gene expression in 
healthy controls and CMC patients with GOF-STAT1 mutations. IL-23 stimulation in 
the absence or presence of fludarabine or TSA in CMC patients overall showing 
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reduced STAT3-dependent gene induction relative to healthy subjects, whilst addition of 
fludarabine or TSA led to a slight increase in gene expression levels. However, when 
fludarabine and TSA were used together, the effect was far more pronounced, 
demonstrating the combination of fludarabine and TSA had a synergistic effect on 
STAT3-induced gene transcription (Figs 6.9 and 6.10). 
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Figure 6.9 Combination of fludarabine and TSA have a synergistic effect on 
STAT3-induced gene transcription in EBV cell lines.  
Expression of c-Fos and SOCS3 genes was assessed in EBV transformed cells derived 
from GOF-STAT1 mutant cells and controls by qRT-PCR (presented as individual data 
(plots) with CI value (boxes) using a pooled estimate of the variability). Cells were 
stimulated with IFN-α (1x103 IU/ml) in the absence or presence of fludarabine (FLU, 
100 μg/ml) and/or TSA (100 ng/ml) for 4 hours. FLU was added 1 hour before cytokine 
stimulation. Column 1: * p≤0.05, ** p≤0.01, CMC vs. HC; Columns 2, 3, 4: * p≤0.05, 
** p≤0.01, IFN-α vs. FLU/TSA/FLU+TSA in CMC. 
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Figure 6.10 Combination of fludarabine and TSA have a synergistic effect on 
STAT3-induced gene transcription in PBMCs.  
Expression of RORc, IL-17, IL-22 and IL-10 genes was assessed in PBMCs from 
GOF-STAT1 mutant cells and controls by qRT-PCR (presented as individual data (plots) 
with CI value (boxes) using a pooled estimate of the variability). Cells were stimulated 
with IL-23 (100 ng/ml) in PHA and IL-2 pre-treated PBMCs with or without 
Fludarabine (FLU, 100 μg/ml) and/or TSA (100 ng/ml) for 4 hours. FLU was added 1 
hour before cytokine stimulation. Column 1: ** p≤0.01, CMC vs. HC; Columns 2, 3, 4: 
* p≤0.05, ** p≤0.01, IL-23 vs. FLU/TSA/FLU+TSA in CMC; ns=no significant. 
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6.4 Summary 
Recent data strongly implicate epigenetic regulation by acetylation of transcriptional 
activity of STAT proteins. In the present chapter, I used a non-selective HDAC inhibitor 
TSA to promote acetylation and investigated its effects on STAT1 and STAT3 activation 
and function. I found addition of TSA did not alter cytokine (IL-23 and IFN-α)-induced 
phosphorylation of STAT1 and STAT3 in either healthy subjects or CMC patients. 
However, TSA was able to normalize the delayed dephosphorylation of STAT1 in cells 
with GOF-STAT1 mutations. Addition of TSA also decreased the cytokine (IFN-α, 
IL-27 and IL-21)-induced STAT1-dependent gene (CXCL10 and IRF1) transcription in 
EBV cells from CMC patients. In contrast, the presence of TSA increased the low levels 
of Th-17 related gene (IL-17A, IL-22 and marginally RORc) expression in 
IL-23-stimulated PBMCs as well as other STAT3-dependent gene (c-Fos and SOCS3) in 
IFN-α-, IL-27- and IL-21-stimulated EBV cells from CMC patients with GOF-STAT1 
mutations. Gene silencing of HDAC1 improved STAT3-dependent gene (RORc, IL-17, 
IL-22, c-Fos and SOCS3) induction in PBMCs or EBV cells either from CMC patients 
or a healthy subject, suggesting that HDAC1 but not HDAC2 or HDAC3 may be 
involved in regulating STAT3 gene transcription. More importantly, restoring 
acetylation by adding TSA could elevate the low levels of the Th-17-related cytokine 
IL-22 in Candida albicans-stimulated PBMCs with GOF-STAT1 mutations. This was 
not seen for IL-17A production where addition of TSA had no effect in CMC patient 
cells but boosted IL-17A levels in cells from healthy controls. Interestingly, combining 
fludarabine and TSA had a synergistic effect on STAT3-induced gene transcription in 
cells from both CMC patients with GOF-STAT1 mutations and healthy controls, 
suggesting that inhibition of STAT1 and enhancing acetylation may act through different 
pathways to regulate STAT3-dependent gene transcription. This effect was not seen in 
Candida albicans-induced cytokine production as fludarabine completely inhibited 
cytokine production. 
The above results demonstrate that the disrupted STAT3 function in cells with 
GOF-STAT1 mutations could be modified by promoting acetylation, which can restore 
impaired STAT3 gene transcription and increase the production of IL-22 known to have 
an important role in fungal immunity.  
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CHAPTER 7 GENERAL DISCUSSION 
 
CMC is a subtle, non-conventional PID where patients suffer with persistent, recurring 
infection of the skin, nails and mucosa with the yeast Candida. Previous research 
focused on the 2 largest groups of patients with CMC-those with the APECED and 
those with isolated AD-CMC. By comparatively studying responses to Candida 
stimulation in these 2 groups, it was found that APECED and AD-CMC patients 
differed markedly in their ability to produce IL-17 in that IL-17A was normal or 
increased in APECED patients but markedly reduced in AD-CMC, indicating for the 
first time that these 2 clinically similar phenotypes have a distinctly different underlying 
disease mechanisms [75]. Subsequent research of APECED patients elegantly explained 
the disease-causing mechanism in the context of existing autoantibodies to cytokines 
IL-17A, IL-17F and IL-22 as well as Type I IFNs [63, 109]. In patients with isolated 
AD-CMC, GOF-STAT1 mutations were identified until recently. How these mutations 
lead to low IL-17 production and susceptible to Candida infections, however, remains a 
crucial research question that needs addressing and was the essence of this study. 
 
7.1 GOF-STAT1 mutations enhance STAT1 activation and gene transcription 
To date, four types of human mutations in STAT1 have been identified, including (1) 
AR complete STAT1 deficiency, (2) AR partial STAT1 deficiency, (3) AD STAT1 
deficiency, and (4) AD gain of STAT1 activity as shown in Table 7.1 [73]. The two 
types of AR STAT1 affect the NTD, CCD, SH2 and TS domains of the STAT1 protein. 
These mutations result in a broad infectious phenotype with susceptibility to 
mycobacteria and viruses, due to the impairment of IFN-γ-mediated and/or 
IFN-α/β-mediated immunity [94, 110, 111]. AD STAT1 deficiency affects DBD, SH2 
and TS domains of the STAT1 protein and selectively predisposes to mycobacterial 
disease, due to the impairment of IFN-γ-mediated immunity, since IFN-α/β-mediated 
immunity is maintained [93, 112-115]. In contrast to these loss-of-function mutations of 
STAT1, the AD gain of STAT1 which affects the CCD and DBD was identified mainly 
in the large subgroup of AD-CMC patients with susceptibility to Candida infections [67, 
 79 
71] as well as patients with disseminated dimorphic fungal infections [116] or an IPEX 
(immunodysregulation polyendocrinopathy enteropathy X-linked syndrome)-like 
phenotype [117].  
 
Table 7.1 Human STAT1 mutations. 
 STAT1 
domain 
affects 
Main cellular phenotype Main clinical phenotype 
AR complete 
STAT1 
deficiency 
NTD, 
SH2 
No STAT1-dependent response 
to IFN-γ, IFN-α/β, IFN-λ and 
IL-27 
Lethal intracellular 
bacteria (mainly 
mycobacteria) and viral 
(mainly herpes) diseases 
 
AR partial 
STAT1 
deficiency 
NTD, 
CCD, TS 
Impaired STAT1-dependent 
response to IFN-γ, IFN-α/β, 
IFN-λ and IL-27 
Curable intracellular 
bacteria (mainly 
mycobacteria) and viral 
(mainly herpes) diseases 
 
AD LOF 
STAT1 
deficiency 
 
DBD, 
SH2, TS 
Impaired STAT1-dependent 
response to IFN-γ and IL-27 
Mycobacterial diseases 
AD GOF 
STAT1 
disorder 
CCD, 
DBD 
Enhanced STAT1-dependent 
response to IFN-γ, IFN-α/β, 
IL-27, IL-6 and IL-21. Impaired 
IL-17 T-cell immunity 
CMC, disseminated 
dimorphic fungal 
infections and 
autoimmunity 
AR, autosomal recessive; AD, autosomal dominant; LOF, loss-of-function; GOF, 
gain-of-function; NTD, N-terminal domain; SH2, Src homology 2 domain; CCD, 
coiled-coil domain; DBD, DNA-binding domain; TS, tail segment domain.  
 
Previous studies have reported the GOF-STAT1 mutations in AD-CMC affected cellular 
responses to the cytokines including IFN-α/β, IFN-γ and IL-27, which predominantly 
activate STAT1 signaling [68]. Consistent with this finding, in chapter 3, I showed that 
cells (PBMCs and EBV transformed cells) with these mutations stimulated with IFN-γ, 
IFN-α and IL-27, generated reproducibly stronger responses than control cells in terms 
of STAT1 phosphorylation, hSIE-binding activity, and the induction of target genes 
(CXCL10 and IRF1). Of note, my results revealed normal IL-21 responses and 
undetectable IL-6 responses in EBV transformed cells. The lack of response to IL-6 can 
be explained by the fact that a small proportion of B cells express IL-6 receptors 
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(IL-6R), which can change dramatically in response to factors such as infection [118]. It 
is likely that the EBV immortalized B cells used in my study lacked IL-6R as opposed 
to the transfected STAT1-deficient sarcoma cell lines with GOF-STAT1 mutant alleles 
used in previous research [68].  
Most of these GOF-STAT1 mutations were found in the CCD of STAT1 protein, in a 
pocket near residues essential for dephosphorylation. My results confirmed that  
mutations at this site resulted in impaired dephosphorylation of STAT1 as reported 
previously [68, 74]. I demonstrated this by showing delayed dephosphorylation of 
STAT1 in IFN-α-stimulated mutant cells or mimicking impaired dephosphorylation with 
pervanadate in healthy cells. However, the delayed dephosphorylation in AD-CMC 
patients may be due to the initial hyper-phosphorylation of STAT1, which then requires 
a longer time to dephosphorylate. I demonstrated that suboptimal stimulation of cells 
with GOF-STAT1 mutations in the presence of staurosporine resulted in lower levels of 
initial phosphorylation of STAT1 that allowed dephosphorylation to occur with similar 
kinetics to normal cells. These results indicated that the initial hyper-phosphorylation 
and impaired dephosphorylation both contribute to the gain of STAT1 activity caused by 
these mutations.  
 
7.2 GOF-STAT1 mutations decrease STAT3 gene transcription 
Several mutations affecting the STAT3/IL-17 pathway resulting in selective 
susceptibility to Candida infections characteristic of CMC have been reported [97]. As 
STAT1 and STAT3 negatively regulate one another in most biological progresses, the 
gain-of-function STAT1 reported in CMC patients may be reducing Th-17 cytokine 
production by interfering with STAT3 signaling.  
In chapter 4, I showed that GOF-STAT1 mutations did not affect STAT3 
phosphorylation, nuclear accumulation and DNA-binding to a non-specific STATs 
consensus binding site element hSIE probe. However, activated STAT3 occupancy at its 
endogenous target gene promoter was decreased in STAT1 mutant cells. Subsequently, 
these mutations had a substantial disruption of STAT3 signaling at the gene transcription 
level, as shown by the markedly decreased gene expression of both Th-17 (RORc, IL-17, 
IL-22) and non-Th-17 (IL-10, c-Fos, SOCS3) genes. The affected cytokine-induced 
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gene transcription was demonstrated including a STAT3-selective cytokine IL-23, which 
has an essential role in differentiation and expansion of Th-17 cells [119], as well as 
other STAT1 and STAT3 activating cytokines IFN-α, IL-21 and IL-27. The broad 
defective of STAT3-inducible gene transcription likely underlie decreased IL-17 
production and susceptibility to fungal infection in these CMC patients and might also 
link to the defective dentition and increased incidence of oesophageal and oral cancers 
seen in CMC patients with GOF-STAT1 mutations. 
Two potential mechanisms might explain how STAT1 hyper-activation in CMC patient 
cells impairs transcription of STAT3-dependent genes: 1) enhanced sequestration of 
STAT3 by hyper-active STAT1 in poorly functional STAT1/3 heterodimers resulting in 
reduced formation of transcriptionally active STAT3 homodimers. I showed in 
semi-quantitative EMSA assays that the STAT3 homodimers and STAT1/3 heterodimers 
formation was comparable in patient and control cells, suggesting that this may not be 
the underlying mechanisms involved. However, I was not able to precisely quantify and 
assess the function of STAT1/3 heterodimers to confirm this; 2) because of the high 
degree of similarity between STAT3 and STAT1 consensus DNA binding sites, the 
constitutively activated STAT1 might compete with normal activated STAT3 for DNA 
binding, thereby preventing STAT3-induced gene transcription. My limited ChIP assay 
data demonstrated STAT3 occupancy of its endogenous c-Fos promoter was retained but 
decreased in STAT1 mutant cells, suggesting that hyper-activate STAT1 competing 
STAT3 DNA-binding may be the underlying mechanisms involved in disruption of 
STAT3 signaling. However, further work is essential to resolve this issue by using ChIP 
sequencing and RNA microarrays as the state-of-the-art technologies providing 
specificity and functional relevance for target gene binding and gene transcription.  
The STAT3 Reporter Assay used for determining the transcriptional activity of STAT3 
in AD-CMC patients technically did not work due to the difficulties in transfecting EBV 
cell line. It is recognized that primary lymphocytes and lymphoid tumor cells, as well as 
cell lines of the lymphoid lineage are difficult to transfect in conventional ways [120]. 
Reported attempts to transduce B and T lymphocytes using retroviruses [121], 
diethylaminoethyl dextran, or liposomes [122] have only had limited success.  
Lentiviral vectors or other approach of cell transfection might be considered to achieve 
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stable and efficient cell transfection in lymphoid cell lines for future work. 
 
7.3 Inhibition of STAT1 enhances STAT3 gene transcription in CMC 
Given that STAT1 hyper-activation is responsible for the low IL-17 production in 
AD-CMC patients, I addressed the question of whether this could be modified by 
inhibiting STAT1.  
In chapter 5, I demonstrated that fludarabine, a STAT1 inhibitor, led to a selective 
inhibition of STAT1 activation and STAT1-target gene (CXCL10 and IRF1) 
transcription without affecting the activation/phosphorylation of STAT3. However, 
addition of fludarabine did increase low levels of STAT3-dependent gene (RORc, IL-17, 
IL-22, c-Fos and SOCS3) expression in AD-CMC patient cells. It is likely that 
abolishing STAT1 activation in CMC patients allows transcriptionally active STAT3 to 
bind to DNA thus enhancing STAT3 signaling. However, inhibiting STAT1 did not 
increase transcription of all STAT3 target genes, as there were barely any changes seen 
with c-Myc and IL-10 gene expression. 
Although fludarabine could improve STAT3-dependent gene transcription, it was unable 
to restore the low levels of C. albicans-induced IL-17 or IL-22 production in cells with 
GOF-STAT1 mutations. Fludarabine is a purine analog, which interferes with DNA 
synthesis. I showed that fludarabine did not affect cell viability as the doses used in 
short time cell culture (as is needed for gene expression assessment), however, it indeed 
cause cell death with long-term culture (as is needed for assessment of cytokine 
production).  
 
7.4 Modification of acetylation alters STAT3 function in CMC 
Although phosphorylation is a crucial post-translational mechanism that regulates the 
activities of STAT proteins, acetylation is also known to be critical post-transcriptional 
mechanism regulating transcriptional activities of STAT proteins [84]. Acetylation of 
histones increases accessibility of nucleosomal DNA to transcription factors and 
generally leads to elevated gene transcription [123]. The characterization of several 
HATs, such as the transcription coactivator of p300 and CREB-binding protein 
(p300/CBP) [124], has provided a potential explanation for the relationship between 
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histone acetylation and gene transcriptional activities. Conversely, deacetylated histones 
with HDACs are often associated with transcriptional repression. In addition to histones, 
other components of the transcription machinery might be acetylated or deacetylated by 
these enzymes such as STAT proteins themselves and directly affect transcription [125]. 
Evidence has emerged revealing the role of acetylation in the regulation of STAT1 and 
STAT3 activities [84]. 
In chapter 6, I used the HDAC inhibitor TSA to investigate whether STAT3 signaling 
defects associated with GOF-STAT1 could be corrected by modifying acetylation. My 
results showed that restoring acetylation with TSA normalized gene transcription levels 
by decreasing STAT1-induced gene (CXCL10 and IRF1) transcription whilst increasing 
transcription of STAT3-inducible gene (IL-17, IL-22, c-Fos, SOCS3 and marginally 
RORc) in cells with GOF-STAT1 mutations. The differentiate regulation of STAT1 and 
STAT3 transcriptional activity by TSA was not seen with cytokine-induced 
phosphorylation. These results are consistent with previous reports, in general, 
acetylation enhances STAT3 signaling whilst negatively regulating STAT1 activity [84]. 
Although how STAT1 and STAT3 acetylation affects phosphorylation is still a matter of 
investigation, it has been proposed that acetylation is required for STAT3 dimerization, 
DNA-binding and gene transcription [126, 127]. Conversely, acetylation impairs STAT1 
DNA-binding and transcriptional activity [128, 129]. These observations may provide 
potential explanations for the opposed regulation of STAT1 and STAT3 gene 
transcription by TSA in the present study. However, the regulation of STAT gene 
transcription by acetylation seemed to be gene dependent as IL-10 and c-Myc gene 
expression was not affected by addition of TSA. 
Despite the increased IL-17A gene expression in the presence of TSA, low C. 
albicans-induced IL-17A cytokine production was maintained in AD-CMC patients. 
The difference in IL-17A gene transcription and cytokine production in the presence of 
TSA in cells with GOF-STAT1 suggested that the modulation of acetylation involved in 
STAT signaling is a dynamic and complex process at multiple levels rather than a 
simple on/off switch and is likely also associated with other post-translational 
modifications. However, it is might be worth to assess IL-17F gene expression and 
cytokine production in these AD-CMC patients as the high titers of IL-17F autoantibody 
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was also detected in APS1 displayed CMC. Importantly, promoting acetylation with 
TSA in cells of AD-CMC not only increased IL-22 gene expression, but also increased 
the C. albicans-induced IL-22 production. Previous studies have suggested that 
although IL-17A and IL-22 are structurally and functionally similar Th-17 cell-derived 
cytokines, IL-22 release is not as strictly limited as IL-17 release [89, 130]. 
Nevertheless, both of them are essential in fungal immunity. My result indicated that 
promoting acetylation with HDAC inhibitor increased IL-22 production that could, at 
least partly, rescue impaired fungal immunity in AD-CMC patients. Class I HDACs 
(HDAC1, 2 and 3) are known to have a role in STAT1 and STAT3 deacetylation [131]. 
Gene silencing using HDAC-specific siRNAs confirmed that HDAC1 was involved in 
modifying STAT3 signaling in this study. This is important because TSA is a broad 
HDACi, which can affect a range of HDAC members that lacks of specificity. However, 
whether inhibiting the activity of HDAC1 can eventually rescue low Th-17 cytokine 
production in AD-CMC patient cells still needs to be addressed in future work.  
Interestingly, promoting acetylation had similar and perhaps even stronger effects in 
healthy controls, suggesting that the altered acetylation may not be the fundamental 
mechanism that responsible for defective IL-17 immunity in AD-CMC. This issue could 
be resolved in future work by assessing the acetylation activity of STAT1 and STAT3 in 
GOF-STAT1 mutant cells. The co-immunoprecipitation assay may provide a better 
understanding of this issue as it can reveal the interaction between phosphorylation and 
acetylation of STAT proteins. Nevertheless, promoting acetylation did rescue the defects 
of STAT3 function caused by these GOF-STAT1 mutations. Indeed, HDAC inhibitors 
are currently under development for use as anticancer agents [132]. They may also offer 
new therapeutic approaches for treating CMC patients with GOF-STAT1 mutations.  
Although either inhibiting STAT1 with fludarabine or enhancing acetylation with TSA 
resulted in increased STAT3 transcriptional activity, the synergistic effects of combined 
TSA and fludarabine on STAT3 gene expression suggested that TSA and fludarabine 
may act through different pathways to modulate STAT3 signaling.  
 
7.6 Future work 
There are a few questions arising from this work that provide a sound basis for further 
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investigation. 
 
7.6.1 Investigate how GOF-STAT1 mutations alter gene-target DNA-binding for 
transcription factors STAT1 and STAT3 
The defects of STAT3 gene transcription in AD-CMC patients may be due to increased 
and accumulated phospho-STAT1 in nuclei competing with STAT3 for DNA-binding. 
Consistent with this, my preliminary data demonstrated the occupancy of STAT3 to its 
target promoter by ChIP assay was marginally decreased in EBV transformed cells with 
GOF-STAT1 mutations. However, to further address this issue, ChIP-seq and RNA 
microarrays should be performed to determine the specificity and functional relevance 
for STAT1 and STAT3 target-gene binding and transcription. This would provide not 
only to further understand the fundamental biologic mechanisms underlying impaired 
fungal immunity in patients with CMC, but also to enhance our knowledge of 
physiological mechanisms of STAT1/3 interaction and cross-regulate function. 
 
7.6.2 Define the role of STAT protein inhibitors in the regulation of STAT1 and STAT3 
activity in GOF-STAT1 mutations 
The negative regulation of STAT activity includes the cytoplasmic and/or nuclear 
proteins families of SOCS [133], PIAS [134] and PTP [81]. The SOCS expressions are 
inducible by ligands and they inhibit STAT proteins by either suppressing JAKs activity 
or by competing binding to the docking site at the cytokine receptor, where STATs must 
bind for their activation. As GOF-STAT1 mutations lead to enhanced STAT1 
activation/phosphorylation, it might be worth to investigate the role of SOCS proteins, 
especially SOCS1 and SOCS3 in CMC patient cells since they can interact directly with 
phosphorylated STATs through a negative feedback loop. Unlike SOCS proteins, PIAS 
proteins possess a certain degree of specificity towards STAT members. PIAS1 and 
PIAS3 bind to and attenuate the transcriptional activity of phosphorylated STAT1 and 
STAT3 by blocking DNA binding, respectively [81]. Recent study has shown that 
PIAS1/STAT1 interaction was enhanced in patients with GOF-STAT1 mutations 
associated with disseminated dimorphic fungal infection [116]. Whether PIAS1/STAT1 
and PIAS3/STAT3 interactions play a role in modifying STAT1 and STAT3 signaling 
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and reducing STAT3-dependent IL-17 production in AD-CMC patients remains to be 
addressed in future work. In addition, PTPs have been reported to dephosphorylate 
either JAK and/or STAT proteins. To date, it has been shown that T cell PTP (TC-PTP) 
and SH2 domain containing PTP-2 (SHP-2) act on STAT1/STAT5 [135] and 
STAT1/STAT3 [136], respectively. However, how PTPs responsible for the impaired 
dephosphorylation of STAT1 caused by mutant STAT1 alleles and whether they have 
any effects on normal phosphorylated STAT3 in AD-CMC patient cells have not yet 
been identified.  
 
7.6.3 Determine the effects of GOF-STAT1 mutations on post-translational 
modifications of STAT1 and STAT3 
Although, promoting acetylation restored the low IL-17 gene transcription activity in 
GOF-STAT1 mutant cells, Candida albicans-induced IL-17 production was barely seen 
any changes. These suggested that post-translational modifications of STAT proteins are 
regulated by far more than phosphorylation and acetylation. Indeed, methylation, 
ubiquitination, SUMOylation, ISGylation and protein-protein interaction, have all been 
described to affect the activities of STATs. Previous research has implicated that STAT3 
is reversibly dimethylated by histone-modifying enzymes only when it is part of a 
promoter-bound complex and this modification affects only subsets of STAT3-activated 
genes [137]. Moreover, a recent report showed the methylation status of STAT1 is 
hypo-methylated in cells with GOF-STAT1 mutations [116], but the methylation status 
of STAT3 and its effect on the subsequent gene transcription are not known. Therefore, 
how the altered methylation status of STAT1 and/or STAT3 contributes to the impaired 
STAT3 gene transcription and low IL-17 production in cells with GOF-STAT1 
mutations needs to be addressed in the future work.  
 
7.6.4 Confirm the mutation-causing mechanisms of CMC 
All the results I have presented in this thesis could provide the potential explanations for 
why GOF-mutations of STAT1 lead to low Th-17 cytokine production and susceptible 
to fungal infections in CMC. However, to further confirm the mutation-causing 
mechanisms in these CMC patients, the human U3A STAT1-deficient sarcoma cell lines 
 87 
need to be used in future work by transfection with either wild type STAT1 allele or 
GOF-STAT1 mutant alleles that identified in CMC patients.  
 
7.7 Conclusion 
Remarkably, profoundly different effects have been identified with respective mutations 
affecting the same human STAT1 gene, resulting in different infectious diseases through 
different molecular and cellular mechanisms. Unlike the LOF mutations, which are 
associated with a predisposition to viral and/or mycobacterial disease, mutations 
affecting the coiled-coil and DNA-binding domains of STAT1 lead to a gain-of-function 
and susceptibility to fungal infections. Enhanced initial phosphorylation and impaired 
dephosphorylation of STAT1 appear to account for its gain-of-function. These 
GOF-STAT1 mutations have a broad defect on STAT3 gene transcription, which is 
likely responsible for the decreased Th-17 (IL-17A and IL-22) cytokine production and 
impaired fungal immunity in AD-CMC patients. The impaired transcriptional activity of 
STAT3 can be rescued by promoting acetylation and/or inhibiting STAT1 activation 
through different regulatory mechanisms. Full elucidation of my finding is likely to 
offer new therapeutic approaches for treating CMC patients with GOF-STAT1 
mutations. 
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Appendix 
 
Table 8.1 Summary of the clinical and genetic data for the patients. 
Patients Gender Origin Age 
at 
study 
Clinical feature 
of CMC 
Autoimmunity Genotype 
Family # 1       
CMCa48 F UK 58 Nails, Skin, 
Scalp 
None A267V 
CMCa34 M UK 33 Nails, Skin, 
Scalp 
None A267V 
CMCa37 F UK 25 Nails, Skin, 
Scalp 
None A267V 
CMCa38 M UK 26 Nails, Skin, 
Scalp 
None A267V 
CMCc3 F UK 7 Skin None A267V 
Family # 2       
CMCa39 F UK 41 Nails, Oral 
cavity, Genital 
mucosa 
None A267V 
CMCa42 M UK 32 Nails, Oral 
cavity 
None A267V 
CMCc43 M UK 7 Oral cavity None A267V 
Family # 3       
CMCa32 F UK 40 Nails, Skin, 
Scalp, Oral 
cavity, 
Oesophagus, 
Gastro tract, 
Genital mucosa 
None R274W 
CMCc7 F UK 11 Skin, Oral 
cavity, Genital 
mucosa 
Thyroid 
autoimmunity 
R274W 
CMCc6 M UK 13 Oral cavity Thyroid 
autoimmunity 
R274W 
Family #4        
CMCc16 M UK 2 Nails, Skin, Oral 
cavity 
None R274W 
CMCa17 F UK 19 Nails, Skin, Oral 
cavity, Genital 
mucosa 
None R274W 
CMCa29 F UK 47 Nails, Skin, Oral 
cavity 
None R274W 
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Family #5       
CMCa31 M UK 55 Nails, Oral 
cavity 
None T288I 
 
Table 8.2 Cell culture reagents and medium used for the research. 
Reagent/medium Company Catalogue No. 
Phosphate Buffered Saline (PBS) Lonza BE10-543F 
Hanks Buffered Saline Solution (HBSS) Lonza BE17-512F 
RPMI 1640 medium Sigma R0883 
Iscove's Modified Dulbecco's Medium 
(IMDM) 
Sigma I3390 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Gibco 41965-039 
Fetal Calf Serum (FCS) Lonza 14401F1 
KnockOut
TM
 Serum Replacement Gibco 10828-028 
Lymphoprep Axis-Shield Diag NYC1114547 
200 mM L-glutamine Solution Sigma G6392 
10x Penicillin-Streptomycin Solution (10
4
 
units per ml penicillin, 10 mg/ml 
streptomycin) 
Sigma P0781 
Phytohemagglutinin (PHA) Sigma L1668 
Amphotericin B Sigma A2942 
RosetteSep
®
 Human CD4
+
 T Cells Enrichment 
cocktail 
StemCell Tech 15062 
CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay 
Promega G5421 
Opti-MEM
®
 I Reduced Serum Medium Invitrogen 31985-062 
Accell siRNA Delivery Media Thermo Scientific B-005000 
Accell 5x siRNA Buffer Thermo Scientific B-002000-UB-100 
Attractene Transfection Reagent Qiagen 1051561 
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Table 8.3 Chemical and biochemical reagents used for the research. 
Chemical/reagent  Company Catalogue No. 
Trichostatin A (TSA) Sigma T8552 
Sodium Orthovanadate  Sigma S6508 
Fludarabine (Fludara) Selleckchem S1491 
Staurosporine Calbiochem 569397 
Sandimmune
®
 / Cyclosporine  Sandoz 478967 
Yeast Nitrogen Base (YNB) BD 239210 
D-Glucose Sigma G8270 
CelLytic
TM
 M Sigma C2978 
Halt
TM
 Phosphatase Inhibitor Cocktail Thermo Scientific 78420 
Complete Protease Inhibitor Mini Tablet Roche Diagnostics 11836153001 
NE-PER Nuclear and Cytoplasmic Extraction 
Kit 
Thermo Scientific 78833 
Bradford Ultra
TM
 Expedeon BFU1L 
Albumin from Bovine Serum (BSA) Sigma A7030 
Bovine Serum Albumin (BSA) Standards Thermo Scientific 23209 
40% Acrylamide/Bis-acrylamide 37.5:1 NBS Biologicals NBS-3600-05 
Ammonium Persulphate (APS) Sigma A3678 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) 
Sigma T22500 
Bromophenol Blue Sigma B1026 
2-Mercaptoethanol Sigma M3148 
PageRuler Prestained Protein Ladder 
10-170kDa 
Thermo Scientific 26616 
Amersham ECL Detection Reagents GE Healthcare RPN2105 
Immobilon Western Chemiluminescent HRP 
Substrate 
Millipore WBKLS0500 
iBlot
®
 Transfer Stack, PVDF Regular package Invitrogen IB4010-01 
Odyssey Infrared EMSA Kit LiCor  
Biosciences 
829-07910 
DL-Dithiothreitol (DTT) Sigma 43816 
Water (DNase, RNase, Protease, free) Sigma W4502 
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BD
TM
 Phosflow Lyse/Fix Buffer (x5) BD 558049 
BD
TM
 Phosflow Perm Buffer III BD 558050 
TransAM STAT3 Kit (human) Active Motif 45196 
TRI
®
 Reagent Sigma 93289 
Superscript II Reverse Transcriptase Invitrogen 18064022 
dNTP Mix Bioline BIO-39028 
pd(N)6 Random Hexamer 5’-Phophate, Sodium 
Salt 
GE Healthcare 27-2166-01 
TaqMan
®
 Gene Expression Master Mix Life Technologies 4369016 
Cignal STAT3 Reporter (luc) Assay Kit Qiagen CCS-9028L 
Protease Inhibitor Cocktail II Millipore 539132 
Formaldehyde Sigma F8775 
Glycine Sigma G8898 
Zysorbin (Staph A membranes) Invitrogen 10-1051-1 
Proteinase K Sigma P2308 
QIAEX II Gel Extraction Kit Qiagen 20021 
SYBR
®
 Green JumpStart
TM
 Taq ReadyMix
TM
  Sigma S4438 
Human IL-17A (homodimer) ELISA Kit eBioscience 88-7176-22 
Human IL-22 ELISA Kit eBioscience 88-7522-22 
O-Phenylenediamine Dihydrochloride (OPD) Sigma P4664 
ExtrAvidin
®
-Peroxidase Sigma E2886 
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Table 8.4 Antibodies used for the research. 
Protein Company Species 
Catalogue 
No. 
Dilution Dilution 
STAT3 (79D7) 
Cell 
Signaling 
Rabbit 4904 1:2000 WB 
Phospho-STAT3 
(Tyr705) (D3A7)
XP
  
Cell 
Signaling 
Rabbit 9145 1:1000 WB 
Phospho-STAT3 
(Ser727)  
Cell 
Signaling 
Rabbit 9134 1:1000 WB 
STAT1 
Cell 
Signaling 
Rabbit 9172 1:1000 WB 
Phospho-STAT1 
(Tyr701) 
Cell 
Signaling 
Rabbit 9171 1:1000 WB 
Phospho-STAT1 
(Ser727)  
Cell 
Signaling 
Rabbit 9177 1:1000 WB 
GAPDH (D16H11)
XP
  
Cell 
Signaling 
Rabbit 4134 1:1000 WB 
Histone H3 (D1H2)
XP
  
Cell 
Signaling 
Rabbit 4499 1:1000 WB 
Lamin A/C 
Cell 
Signaling 
Rabbit 2032 1:1000 WB 
Immunoglobulin 
HRP 
Dako Rabbit P0448 1:2000 WB 
HDAC1 Abcam Rabbit ab7028 1:1000 WB 
HDAC2 Abcam Rabbit ab16032 1:1000 WB 
HDAC3 Abcam Rabbit Ab16047 1:1000 WB 
STAT3 (C-20) Santa-cruz Rabbit sc-482 1:1 EMSA/ChIP 
STAT1 (E-23) Santa-cruz Rabbit sc-346 1:1 EMSA 
Negative ChIP 
antibody (IgG) 
Millipore Rabbit PP64B 1:1 ChIP 
Alexa Fluor® 647 
STAT1 (pY701) 
BD 
Biosciences 
Mouse 51-9006596 1:10 
Flow 
Cytometry 
Human IL-10 
(Capture) 
BD 
Biosciences 
Rat 554705 1:1000 ELISA 
Human IL-10 
(Detection) 
BD 
Biosciences 
Rat 554499 1:500 ELISA 
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Table 8.5 Cytokines used for the research. 
Cytokine Company Catalogue No. 
Recombinant human IL-6 R&D Systems  206-IL 
Recombinant human IL-23 R&D Systems 1290-IL 
Recombinant human IFN-γ R&D Systems 285-IF 
Recombinant human IL-27 R&D Systems 2526-IL 
Recombinant human IL-12 R&D Systems 219-IL 
Human IL-21 Cell Signaling  8920 
Human IL-2 (Proleukin) Novartis n/a 
Human IFN-α (IntronA Interferon 
alfa-2b) 
Merck Sharp & Dohme n/a 
Human IL-17A Recombinant protein 
(1 μg/ml) (ELISA standard) 
eBioscience 39-8179-60 
Human IL-22 Recombinant protein (1 
μg/ml) (ELISA standard) 
eBioscience 39-8229-60 
Human IL-10 Recombinant protein  
(100μg/ml) (ELISA standard) 
BD Biosciences 554611 
 
Table 8.6 The sequences of STAT probes and competitor oligonucleotides used in 
the EMSA experiments. 
Probe/Competitor Sequence (5’-3’) 
hSIE:  5’-GTCGACATTTCCCGTAAATC -3’ 
5’-GATTTACGGGAAATGTCGAC-3’ 
IL-17 5’-GTCGACATTTCCGGAAATC-3’ 
5’-GATTTCCGGAAATGTCGAC-3’ 
GAS 5’-ATGTATTTCCCAGAAA-3’ 
5’-TTTCTGGGAAATACAT-3’ 
ISRE 5’-GATCGGGAAAGGGAAACCGAAACTGAA-3’ 
5’-TTCAGTTTCGGTTTCCCTTTCCCGATC-3’ 
STAT3 5’-GATCCTTCTGGGAATTCCTAGATC-3’ 
5’-GATCTAGGAATTCCCAGAAGGATC-3’ 
The labeled oligonucleotides were purchased from Eurofins with 5’-DY682 
modification, the unlabeled oligonucleotides, as refer to competitors were purchased 
from Sigma. 
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Table 8.7 Primers used for TaqMan Real Time PCR gene expression assay. 
Gene  Primers 
RORc Applied Biosystems: Assay Number: Hs01076122_m1 
IL-22 Applied Biosystems: Assay Number: Hs01574154_m1 
IL-17A Applied Biosystems: Assay Number: Hs00174383_m1 
IL-10 Applied Biosystems: Assay Number: Hs00961622_m1 
c-Fos Applied Biosystems: Assay Number: Hs00170630_ml 
c-Myc Applied Biosystems: Assay Number: Hs00153408_m1 
SOCS3 Applied Biosystems: Assay Number: Hs02330328_s1 
T-bet Applied Biosystems: Assay Number:Hs00203436_m1 
CXCL10 Applied Biosystems: Assay Number:Hs01124251_g1 
IRF1 Applied Biosystems: Assay Number:Hs00971960_m1 
18S F    5’-CGAATGGCTCATTAAATCAGTTATGG-3’ 
R    5’-TATTAGCTCTAGAATTACCACAGTTATCC-3’ 
Probe 5’-FAM-TCCTTTGGTCGCTCGCTCCTCTCCC-TAMRA-3’ 
 
Table 8.8 siRNA used for gene silencing studies. 
siRNA Target Gene Catalogue Number (Dharmacon) 
Accell Non-Targeting siRNA Pool D-001910-10 
SMARTpool Accell HDAC1 E-003493-00-0005 
SMARTpool Accell HDAC2 E-003495-00-0005 
SMARTpool Accell HDAC3 E-003496-00-0005 
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Table 8.9 Buffers used for Western blotting. 
Buffer alias Components 
Whole Cell Lysis Buffer 10 ml CelLytic M, 100 μl of 100x Halt Phosphatase 
Inhibitor Cocktail, 1 Complete Protease Inhibitor Mini 
Tablet 
Low Gel Buffer (LGB) 1.5 M Tris, pH 8.8, 0.4% (w/v) SDS 
Upper Gel Buffer (UGB) 0.5 M Tris, pH 6.8, 0.4% (w/v) SDS 
Stacking Gel Buffer 
(SGB) 
40% Acry/Bis diluted to 4.5% with dH2O and 4x UGB 
10% Acrylamide Gel 1.5 ml 40% Acry/Bis, 1.5 ml 4x LGB, 3 ml dH2O, 30 μl 
20% APS, 10 μl TEMED 
Stacking Gel 2.5 ml SGB, 15 μl 20% APS, 5 μl TEMED 
Sample Buffer x5 10 ml 10x UGB, 1 g SDS, 8 ml Glycerol, 1.5 ml 
Bromophenol blue (0.5% made up in EtOH), prior to 
sample add 200 μl 2-mercaptoethanol into 1 ml aliquots 
Running Buffer 250 mM Tris, 2 M Glycine, 10% (w/v) SDS 
Tris-Buffered 
Saline-Tween (TBS/T) 
10 mM Tris-HCl, pH 7.4, 0.15 M NaCl and 0.2% (v/v) 
Tween-20 
 
Table 8.10 Buffers used for EMSA. 
Buffer alias Components 
Hypotonic Buffer 10 mM HEPES, pH7.6, 1.5 mM MgCl2, 10 mM KCl, 1 mM 
DTT, 10 mM NaF, 1 mM Na3VO4, 0.1% Nonidet P-40 
alternative (v/v), 1 Complete protease inhibitor Mini Tablet per 
50 ml 
High Salt Buffer 20 mM HEPES, pH7.9, 420 mM NaCl, 20% Glycerol (v/v), 1 
mM DTT, 10 mM NaF, 1 mM Na3VO4, 1 Complete protease 
inhibitor Mini Tablet per 50 ml 
Annealing Buffer 10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA 
Tris/Borate/EDTA 
(TBE) x5 
0.445 M Tris-base, 0.445 M Boric acid, 0.01 M EDTA 
Running Buffer 
(0.5xTBE) 
44.5 mM Tris-base, 44.5 mM Boric acid, 1 mM EDTA 
Non-denaturing 
Polyacrylamide gel 
(5%) 
2.6 ml 5x TBE, 3.2 ml 40 % Acry/Bis, 19.1 ml dH2O, 88 μl 20% 
APS, 25 μl TEMED 
STAT Protein  
Optimal Binding 
Reaction 
1x Binding Buffer, 1 mM DTT, 1 mM EDTA, 50 mM Tris-HCl 
pH8.0, 210 mM NaCl, 10% glycerol, 1 μg Poly (dI-dC), 0.5 μg 
Salmon Sperm, 1 pmol labelled probe and 10 μg nuclear extract 
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Table 8.11 Buffers used for ChIP assay. 
Buffer alias Components 
SDS Lysis Buffer 1% (w/v) SDS, 10 mM EDTA, 50 mM Tris pH8.1 
Dilution Buffer 1.1% (v/v) Triton, 1.2 mM EDTA, 16.7 mM Tris-HCl pH8.1, 
167 mM NaCl 
Low Salt Buffer 1% (v/v) Triton, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 150 mM 
NaCl 
High Salt Buffer 1% (v/v) Triton, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 500 mM 
NaCl 
LiCl Wash Buffer 0.25 mM LiCl, 1% (v/v) NP40, 1 mM EDTA, 10 mM Tris-HCl 
pH8.1 
Elution Buffer 0.084g NaHCO3 in 9 ml water 
TE Buffer 10 mM Tris-HCl pH8.1, 1 mM EDTA 
All buffers (except elution and TE buffer) were added protease inhibitors (Millipore) 
before using at final concentration of 4 μl/ml. 
 
Table 8.12 Buffers used for ELISA. 
Buffer alias Components 
Coating Buffer 15 mM Na2HPO4, 20 mM NaH2PO4.H2O 
Wash Buffer PBS pH7.2, 0.1% (v/v) Tween-20 
Blocking Buffer PBS pH7.2, 1% (w/v) BSA 
Diluent Buffer PBS pH7.2, 1% (w/v) BSA, 0.1% (v/v) Tween-20 
Citrate Phosphate 
Buffer 
25 mM Citric acid, 50 mM Na2HPO4, 20 mM Na2HPO4.2H2O 
Substrate  1 tablet OPD, 13 ml Citrate Phosphate Buffer, 6 μl H2O2 
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Table 8.13 Presentations generated from this study. 
Conference Title Date Venue 
Oral presentation 
North East Postgraduate 
Conference 
Gain-of-function STAT1 
mutation decreases 
STAT3-inducible gene 
transcription in patients with 
Chronic Mucocutaneous 
Candidiasis  
October 
2013 
Newcastle 
University, 
UK 
British Society for 
Medical Mycology 
Decreased STAT3-inducible 
gene transcription in patients 
with gain-of-function STAT1 
mutations 
April  
2013 
Newcastle, 
UK 
North East Postgraduate 
Conference 
Gain-of-function STAT1 
mutations alter STAT3 
activation 
October 
2012 
Newcastle 
University, 
UK 
Poster presentation 
British Society for 
Immunology Congress 
Gain-of-function STAT1 
mutation decreases 
STAT3-inducible gene 
transcription in patients with 
Chronic Mucocutaneous 
Candidiasis 
December 
2013 
Liverpool, 
UK 
 
British Society for 
Immunology Summer 
School 
Decreased STAT3-inducible 
gene transcription in patients 
with gain-of-function STAT1 
mutations 
August 
2013 
Newcastle 
University, 
UK 
Institute of Cellular 
Medicine Research Day 
Decreased STAT3-inducible 
gene transcription in patients 
with gain-of-function STAT1 
mutations 
June  
2013 
Newcastle 
University, 
UK 
15
th
 Biennial Meeting of 
the European Society of 
Immunodeficiencies 
Gain-of-function STAT1 
mutations alter STAT3 
activation 
October 
2012 
Florence, 
Italy 
Institute of Cellular 
Medicine Research Day 
Gain-of-function STAT1 
mutations alter STAT3 
activation 
June  
2012 
Newcastle 
University, 
UK 
British Society for 
Immunology Congress  
Effect of cytokine-induced 
STAT1 signaling on STAT3 
activation and binding 
December 
2011 
Liverpool, 
UK 
 
North East Postgraduate 
Conference 
Effect of cytokine-induced 
STAT1 signaling on STAT3 
activation and binding 
October 
2011 
Newcastle 
University, 
UK 
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